





















Abstract	From	2015-2016	 I	 undertook	 the	Master	 of	 Philosophy	 in	Applied	Epidemiology	(MAE)	whilst	under	the	employment	of	the	Murdoch	Childrens	Research	Institute	(MCRI)	 in	 Melbourne	 as	 a	 research	 officer	 for	 a	 study	 based	 in	 the	 People’s	Democratic	Republic	of	Laos	(Lao	PDR).	To	satisfy	the	requirements	of	the	MAE,	I	completed	 projects	 in	 the	 areas	 of	 data	 analysis,	 public	 health	 surveillance,	epidemiological	research	and	outbreak	investigation.		The	 work	 I	 was	 employed	 for	 with	 MCRI	 formed	 the	 basis	 of	 my	 data	 analysis	competency.	The	aim	of	this	project	was	to	determine	the	pneumococcal	conjugate	vaccine	 (PCV)	 coverage	 required	 to	 achieve	 herd	 immunity	 using	 pneumococcal	carriage	surveillance	at	Mahosot	Hospital	in	Lao	PDR.	Beyond	the	analysis	of	these	data,	I	was	responsible	for	overseeing	and	coordinating	the	larger	body	of	work	for	this	project	based	in	Lao	PDR.	This	work	is	ongoing	and	a	final	publication	will	be	published	later	in	2017.			With	 guidance	 from	 my	 field	 supervisor,	 I	 was	 responsible	 for	 establishing	 the	epidemiology	 of	 acute	 gastroenteritis	 (AGE)	 in	 Kiribati	 pre-	 and	 post-rotavirus	(RV)	 vaccine	 introduction.	 As	 part	 of	 this	 review,	 I	 established	 post-marketing	surveillance	of	intussusception	(IS)	as	part	of	RV	vaccine	introduction.	The	World	Health	 Organization	 (WHO)	 recommends	 the	 surveillance	 of	 IS	 post-RV	 vaccine	introduction	due	 to	experiences	with	a	previous	 formulation	of	 the	vaccine.	This	evaluation	is	ongoing	and	will	be	completed	in	2017.		In	 response	 to	 vaccine	 preventable	 disease	 (VPD)	 outbreaks	 in	 Lao	 PDR,	 the	Ministry	 of	 Health,	 National	 Immunization	 Programme	 (NIP)	 requested	information	 regarding	 evidence	 of	 serological	 protection	 of	H.	 influenzae	 type	 b	(Hib)	in	their	population.	This	study	was	the	basis	of	my	epidemiological	research	for	the	MAE.	The	results	from	this	study	would	provide	data	on	Hib	protection	in	their	 population	 to	 help	 inform	 NIP	 if	 changes	 to	 their	 current	 schedule	 were	necessary.		
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population	 lies	 in	 the	 effect	 of	 herd	 immunity.	Many	 countries	 in	 resource-poor	settings,	 such	as	Southeast	Asia,	do	not	have	 robust	 systems	 to	monitor	 invasive	pneumococcal	 disease	 (IPD),	 pneumonia	 and/or	 community	 carriage,	 making	 it	difficult	to	determine	the	herd	immunity	effects	of	PCV	in	the	population.	Beyond	the	added	benefit	of	describing	pneumococcal	carriage	in	Lao	PDR,	the	data	from	this	study	will	add	to	the	body	of	data	in	the	PCV	evaluation	being	prepared	for	the	NIP,	 continuing	 the	 support	 for	use	of	PCV	 in	Lao	PDR.	The	 surveillance	method	proposed	in	this	study	can	be	implemented	quickly	in	sentinel	hospital	sites,	with	an	easily	accessible	population	and	isn’t	dependent	on	pre-vaccine	data,	making	it	adaptable	 to	 other	 low	 and	 middle-income	 countries	 (LMICs).	 However	determination	 of	 PCV	 coverage	 is	 a	 challenge	 and	 novel	 methods	 need	 to	 be	considered.	This	is	 important	as	many	countries	are	considering	the	introduction	of	 PCVs	 in	 the	 region	 and	 face	 a	 similar	 situation	 to	 Lao	 PDR.	 The	 use	 of	 this	method	will	 provide	 other	 LMICs	with	 a	method	 to	 observe	 the	 effect	 of	 PCV	 in	their	country,	supporting	their	use.		





Background/aims:	 People’s	 Democratic	 of	 Laos	 (Lao	 PDR)	 introduced	 13-valent	pneumococcal	 conjugate	 vaccine	 (PCV13)	 in	October	 2013	 for	 children	 up	 to	 12	months	of	age.	The	primary	aim	of	this	study	is	to	determine	the	PCV13	coverage	needed	 to	 show	 evidence	 of	 herd	 immunity	 using	 nasopharyngeal	 (NP)	pneumococcal	carriage	surveillance	in	hospitalised	children	in	Lao	PDR.	Secondary	aims	 were	 to	 describe	 the	 epidemiology	 of	 cases	 and	 describe	 overall	pneumococcal	 carriage,	 VT	 carriage	 and	 NVT	 carriage	 among	 vaccinated	 and	undervaccinated	cases.		
Methods:	 Children	 2-59	 months	 of	 age	 admitted	 to	 Mahosot	 Hospital,	 Vientiane	with	acute	respiratory	infection	(ARI)	were	prospectively	enrolled	from	December	2013	to	July	2016,	and	had	a	NP	swab	collected.	Pneumococcal	carriage	status	was	determined	 using	 lytA	 real-time	 quantitative	 PCR	 (qPCR),	 with	 positives	 and	equivocals	 serotyped	 by	 microarray.	 Monthly	 PCV13	 vaccine-type	 (VT)	 carriage	rates	 were	 determined	 in	 undervaccinated	 and	 vaccinated	 children.	 The	 PCV13	vaccination	rate	was	calculated	using	7-month	rolling	intervals	each	month	by	the	number	of	cases	vaccinated	based	on	written	records	(mother	child	health	(MCH)	card	 or	 health	 centre	 immunisation	 registry)	 and	 the	 total	 number	 of	 cases	enrolled	 each	month.	Herd	 immunity	 effects	were	determined	by	 calculating	 the	risk	 of	 VT	 carriage	 among	 vaccinated	 and	undervaccinated	 children.	A	 risk	 ratio	equivalent	 to	 1	 was	 deemed	 as	 herd	 immunity	 effects	 being	 achieved	 in	 the	population.		








3.1.	Pneumococcal	disease		In	 2000,	 it	 was	 estimated	 pneumococcal	 infections	 were	 responsible	 for	 about	826,000	 deaths	 in	 children	 1-59months	 of	 age	 (1).	 Pneumonia	 is	 the	 second	leading	 cause	 of	 deaths	 in	 children	 under	 the	 age	 of	 5	 years	 globally	 (2),	 with	pneumococcus	being	the	most	common	cause	of	bacterial	pneumonia	(3).	Almost	all	pneumonia-related	deaths	occur	 in	 low	and	middle-income	countries	 (LMICs)	where	children	are	poor,	timely	access	to	health	services	may	be	difficult	or	even	impossible	 and	 where	 risk	 factors	 for	 more	 frequent	 and	 severe	 disease	 are	common	(4).	Ninety-eight	percent	of	all	pneumonia	deaths	in	children	less	than	5	years	of	age	occur	in	just	68	LMICs	(5).			
Streptococcus	 pneumoniae	 or	 pneumococcus	 is	 a	 Gram-positive	 bacterium	 that	naturally	resides	in	the	nasopharynx	of	humans.	Nasopharyngeal	(NP)	carriage	is	common	and	most	carriers	are	healthy	(6).	Transmission	occurs	via	direct	contact	with	 respiratory	 secretions	 from	 carriers	 to	 non-carriers	 (1).	 Acquisition	 and	subsequent	 infection	with	pneumococcus	 is	 the	precursor	 to	disease	 (7,	 8),	with	the	highest	pneumococcal	carriage	rates	in	children	during	their	first	2	years	of	life	(8).	From	this	point,	pneumococcus	can	be	spread	to	others	and	also	gain	access	to	other	sites	 in	 the	body	such	as	 the	 lungs,	which	 then	can	 lead	 to	pneumonia	 (8).	Thus	 far	 there	 have	 been	 over	 90	 unique	 serotypes	 identified	 however	 not	 all	serotypes	 cause	 disease.	 Diseases	 caused	 by	 pneumococcus	 include	 pneumonia,	meningitis,	febrile	bacteraemia,	otitis	media,	sinusitis	and	bronchitis	(1).			
3.2.	Pneumococcal	Conjugate	Vaccine	(PCV)	In	2007,	WHO	recommended	the	use	of	pneumococcal	conjugate	vaccines	(PCVs)	in	all	countries,	urging	the	highest	priority	for	introduction	given	to	countries	with	high	 pneumonia	 and	 under	 5	 mortality	 rates	 (1).	 In	 February	 2000,	 the	 United	States	 (US)	Food	and	Drug	Administration	 (FDA)	 licenced	 the	 first	PCV,	 7-valent	PCV	 (PCV7)(9).	 PCV7,	 also	 known	 as	 Prevenar®,	 contained	 7	 pneumococcal	polysaccharides	 (4,	 6B,	 9V,	 14,	 18C,	 19F	 and	 23F)	 conjugated	 to	 a	 non-toxic	diphtheria-toxin	 variant	 carrier	 protein,	 CRM197	 (9).	 Because	 of	 issues	 with	
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serotype	 replacement	 and	 coverage	 of	 other	 important	 serotypes	 in	 LMICs,	 new	formulation	PCV’s	are	now	available,	with	the	two	currently	licenced	being	PCV10	and	 PCV13,	 licenced	 in	 2009	 and	 2010	 respectively.	 PCV13,	 also	 known	 as	Prevenar13®,	has	the	same	components	as	PCV7,	with	the	addition	of	addition	of	6	serotypes;	1,	3,	5,	6A,	7F	and	19A.			
3.3.	Impact	of	PCV	on	invasive	pneumococcal	disease	(IPD)	Evidence	 from	 high	 income	 countries	 (HICs)	 that	 have	 adopted	 PCVs	 into	 their	National	 Immunization	 Programmes	 (NIPs),	 have	 shown	 their	 use	 can	 prevent	much	 morbidity	 and	 mortality	 (9,	 10).	 Since	 the	 use	 of	 PCV7,	 countries	 that	adopted	the	use	of	the	vaccine	reported	significant	declines	in	IPD.	In	a	review	by	Feikin	 et	 al.	 (2013),	 reductions	 in	 invasive	 pneumococcal	 disease	 (IPD)	 up	 to	 7	years	post-PCV7	 introduction	were	summarised.	Feikin	et	al.	 (2013)	 included	21	datasets	 for	 their	 analysis	 from	 4	 geographical	 regions	 (North	 America,	 Europe	Australasia,	South	America).	In	children	<5years	of	age,	by	the	first	year	of	use,	IPD	caused	by	vaccine-types	(VTs)	significantly	decreased	from	a	risk	ratio	of	0.34	to	0.14,	 further	 decreasing	 after	 7	 years	 of	 use	 to	 0.03(11).	 Focusing	 on	pneumococcal	 meningitis,	 Htar	 et	 al.	 (2013)	 assessed	 the	 impact	 of	 PCV7	 on	pneumococcal	 meningitis.	 Seventeen	 articles	 were	 included	 in	 this	 review	 from	two	 continents;	 Western	 Europe	 and	 North	 America.	 Comparing	 pre-	 and	 post-vaccination	periods,	reductions	ranging	from	59.2%	in	the	US	to	100%	in	Belgium	in	VT	pneumococcal	meningitis	incidence	were	shown	in	vaccine-eligible	children	(12).			
3.4.	Herd	immunity	The	 reductions	 in	 IPD	 after	 PCV	 introduction	 were	 not	 limited	 to	 vaccinated	populations,	extending	to	unvaccinated	groups,	namely	older	children	and	adults.	Herd	 immunity,	 or	 herd	 protection/indirect	 effect	 of	 vaccination,	 is	 where	unvaccinated	populations	are	also	protected	from	disease.	For	PCV,	the	reduction	in	 NP	 carriage	 of	 VTs	 caused	 by	 vaccine	 use	 interrupts	 transmission	 to	unvaccinated	 contacts	 (9,	 13).	 The	 use	 of	 PCV	 resulted	 in	 reductions	 of	pneumococcal	disease	burden	in	the	non-immunised	adult	population,	where	the	burden	 in	 terms	 of	 mortality,	 morbidity	 and	 hospitalisation	 costs	 of	 IPD	 and	
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community-acquired	pneumonia	(CAP)	is	larger	than	in	children	(13).	In	terms	of	cost	 saving,	 Ray	 et	 al.	 (2006)	 estimated	 a	 15-fold	 increase	 in	 cost-effectiveness	when	herd	immunity	was	considered	in	US	estimates	(14).	In	terms	of	actual	dollar	value,	McIntosh	et	al.	(2005)	estimated	that	the	direct	cost	of	per	life	year	gained	in	the	UK	when	herd	immunity	was	considered	equated	to	4,360	pounds	(15).	Thus	to	get	the	maximum	benefit	of	PCV	use	in	a	population,	herd	immunity	needs	to	be	considered.		Figure	1	is	an	excerpt	from	Feikin	et	al.	(2013)	and	illustrates	the	impact	of	PCV7	on	 VT	 IPD	 in	 HICs	 up	 to	 7	 years	 post	 PCV7	 introduction.	 From	 Figure	 1,	 the	greatest	 reductions	 are	 seen	 in	 children	 <5	 years	 of	 age,	 as	 described	 in	 the	previous	section,	but	there	are	also	reductions	in	adult	age	groups	over	this	7-year	period	(11).			
Figure	1:	Post-PCV7	introduction	invasive	pneumococcal	disease	caused	by	vaccine	types	summary	rate	ratios	from	random	effects	meta-analysis.	Adapted	from	Feikin	et	al.	(2013)	
		In	a	recent	systematic	review	and	meta-analysis	by	Shiri	et	al.	(2017),	IPD	due	to	PCV7	 serotypes	 in	 countries	 with	 mature	 PCV	 programmes	 has	 been	 all	 but	eliminated	due	 to	herd	 immunity	 (16).	They	also	predicted	 that	 the	 residual	 IPD	caused	 by	 the	 additional	 6	 VTs	 in	 PCV13	will	 be	 halved	 after	 a	mean	 period	 of	about	3	years	and	nearly	eradicated	(90%	reduction)	after	about	9	years	of	PCV13	use	 (16).	However	 as	 highlighted	by	Goldblatt	 et	 al.	 (2017)	using	 the	 Shiri	 et	 al.	(2017)	paper,	most	of	 the	data	 for	 the	 indirect	 effect	 of	PCV	are	 from	HICs	with	mature	 surveillance	 systems	 where	 PCV	 was	 introduced	 into	 the	 infant	immunisation	programmes	 soon	after	 licensure	 (16,	17).	 Shiri	 et	 al.	 (2017)	used	data	 from	 only	 4	 LMICs,	 with	 none	 of	 them	 from	 Asia,	 raising	 questions	 of	 the	applicability	of	the	data	on	indirect	effect	of	PCV	to	LMICs	(16,	17).	
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	The	extent	of	herd	immunity	is	dependent	on	coverage	and	serotype	distribution	in	 the	 population.	 This	 becomes	 particularly	 important	 when	 considering	 the	impact	 of	 PCV	 in	 LMICs.	 Tsaban	 et	 al.	 (2017),	 stated	 that	 ‘profound	 indirect	protection	 can	 only	 be	 achieved	 in	 populations	 with	 high	 (>70-80%)	 vaccine	coverage’,	where	extensive	sustained	interruption	of	VT	transmission	occurs	(13).	The	length	of	time	since	PCV	introduction	also	plays	a	role;	countries	with	mature	PCV	 programmes	 seeing	 a	 greater	 vaccine	 impact	 in	 both	 child	 and	 adult	populations	(13).	However	 in	a	comment	piece	by	Klugman	and	Rodgers	(2017),	reported	IPD	reduction	 incidence	 in	Europe	 is	 less	 than	that	seen	 in	 the	US	(18).	Reasons	for	this	are	the	variety	in	vaccine	coverage	rates	in	different	countries	and	a	wider	diversity	of	pneumococcal	serotypes	causing	disease	(19).	These	reasons	are	a	concern	for	LMICs,	which	see	lower	coverage	of	PCV	and	greater	diversity	of	pneumococcal	 serotypes	 causing	 disease	 (16,	 18).	 However,	 the	 ecology	 of	pneumococcal	transmission	in	LMICs	may	be	very	different	to	what	is	seen	in	HICs	(16).	 Thus	 perhaps,	 different	 levels	 of	 vaccine	 coverage	 may	 be	 adequate	 to	achieve	herd	immunity.	Also	different	formulations	of	pneumococcal	vaccines	may	have	a	greater	impact	on	pneumococcal	disease	in	LMIC	settings.	More	research	is	required	to	assess	the	indirect	affects	of	PCV	in	these	settings.			
3.5.	Measuring	direct	and	indirect	effects	of	PCV	on	pneumococcal	
disease	Determining	 direct	 and	 indirect	 effects	 of	 PCV	 on	 pneumococcal	 disease	 are	difficult	because	of	the	complex	nature	of	pneumonia	and	also	the	low	sensitivity	in	identifying	pneumococcus	as	the	cause	of	invasive	disease	(20).	Pneumonia	can	be	caused	by	range	viruses,	bacteria	or	fungi,	with	the	progression	of	disease	also	affected	by	a	range	of	socioeconomic	factors.	In	addition,	as	the	lungs	are	internal,	the	 methods	 for	 diagnosis	 range	 from	 invasive,	 such	 as	 a	 lung	 puncture	 to	observatory	such	as	a	chest	x-ray	to	try	and	determine	the	aetiological	agent	(21).	Furthermore,	to	definitively	diagnose	IPD,	pneumococcus	must	be	isolated	from	a	sterile	 site	 such	 as	 blood,	 cerebrospinal	 fluid,	 ascetic	 fluid,	 etc.	 Pneumococcus	 is	difficult	 to	detect	 in	 the	 laboratory,	and	newer	diagnostic	 tests	are	adding	 to	our	understanding	of	 the	burden	of	disease.	 In	addition	 to	 the	 inherent	difficulties	of	pneumococcal	 isolation	 from	 patient	 samples,	 LMICs	 have	 the	 added	
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disadvantages	 of	 problems	 with	 basic	 microbiological	 culture	 of	 organisms,	leading	to	further	reductions	in	culture	sensitivity	(20,	22).	Due	to	the	limitations	of	 current	 diagnostic	 methods	 and	 pre-diagnostic	 antibiotic	 use,	 pneumonia	aetiology	 studies	 often	 underestimate	 the	 true	 burden	 of	 pneumococcal	 disease	(20,	23).		The	cornerstone	for	support	of	PCV	introduction	and	continued	use	in	NIPs	is	IPD	surveillance	 (22).	 The	 recommendation	 for	 accurate	 vaccine	 assessment	 is	consistent	 surveillance	 for	 a	 minimum	 2	 years	 pre-vaccine	 and	 5	 years	 post-vaccine	introduction	(22).	The	reality	for	most	LMICs	is	they	are	unable	or	do	not	have	 systems	 in	 place	 for	 robust	 disease	 surveillance	 to	 show	 herd	 immunity,	making	 it	 very	 difficult	 to	 determine	 if	 they	 are	 getting	 the	maximum	benefit	 of	PCV	 in	 their	population	 (6).	This	becomes	even	more	crucial	when	assessing	 the	value	of	PCV	in	their	immunisation	programs.	Thus	for	LMICs,	new	methods	need	to	be	assessed	such	as	syndromic	surveillance	(22)	or	the	use	of	a	proxy	such	as	VT	carriage	to	determine	the	impact	of	PCV	in	their	population.			




		Carriage	is	becoming	frequently	included	in	PCV	evaluation	studies,	as	PCV	use	has	seen	the	decrease	and/or	near	elimination	of	VTs	from	the	nasopharynx.	This	has	led	 to	 a	 decrease	 in	 transmission	 of	 VTs	 and	 subsequent	 reductions	 in	pneumococcal	 disease	 (18).	 Therefore,	 the	 PCV	 effect	 of	 NP	 carriage	 in	 healthy	carriers	plays	a	major	role	in	the	control	of	pneumococcal	disease	and	may	be	the	key	to	the	control	of	pneumococcal	disease	in	countries	that	are	unable	to	achieve	PCV	coverage	 in	 their	entire	population	(18).	However	questions	remain	on	how	the	NP	carriage	decline	of	VTs	can	be	extrapolated	to	declines	 in	VT	IPD	and	the	role	of	NVTs	in	IPD,	as	not	all	serotypes	carried	cause	disease	(6).		
3.7.	Carriage	surveillance	and	herd	immunity	Therefore,	could	carriage	surveillance	be	used	to	estimate	the	coverage	required	to	show	herd	immunity	in	these	populations?	This	concept	has	been	explored	thus	far	by	 Loughlin	 et	 al.	 (2014)	 and	 Grant	 et	 al.	 (2016)	 in	 populations	 in	 Boston	 and	American	 Indians	 respectively.	 Both	 populations	 had	 used	 PCV7	 in	 their	 routine	immunisation	since	2000,	so	the	herd	immunity	effects	were	only	measured	in	the	additional	6	serotypes	covered	by	PCV13.		
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	Red	line	=	carriage	prevalence;	Histograms	=	PCV13	coverage;	Histogram	bar	outlined	in	black	identifies	the	month	when	significant	reduction	was	achieved	compared	to	the	pre-PCV13	introduction	period		From	 the	 Loughlin	 and	 the	 Grant	 studies,	 the	 prospect	 of	 using	 pneumococcal	carriage	 surveillance	 to	 show	effects	of	herd	 immunity	may	prove	 to	be	a	 viable	option	 for	 LMICs	 considering	 the	 use	 of	 PCV	 in	 their	 NIPs.	 Using	 carriage	surveillance	 bypasses	 the	 need	 for	 robust	 disease	 surveillance	 and	 can	 be	implemented	as	the	vaccine	is	being	introduced	into	the	population	with	little	pre-vaccine	 introduction.	However	both	of	 these	studies	use	community	samples	not	samples	collected	from	children	suffering	from	acute	respiratory	illness	(ARI).		As	 pneumococcal	 carriage	 is	 a	 precursor	 to	 disease,	 it	 is	 assumed	 that	 if	 VT	carriage	declines,	VT	disease	 also	declines.	However	 there	 is	not	 always	 a	direct	correlation	between	carriage	serotypes	and	those	isolated	in	invasive	disease	(29).	Environmental	 factors,	 host	 factors	 and	 bacterial	 virulence	 all	 play	 a	 role	 in	development	of	disease.	What	has	been	shown	is	the	presence	of	higher	carriage	of	pneumococcus	 in	 children	 with	 ARI	 or	 pneumonia	 (30).	 Thus	 those	 that	 suffer	from	respiratory	illness	are	at	a	higher	risk	of	disease	to	begin	with.	The	isolation	of	pneumococcus	from	the	NP	of	children	hospitalised	with	ARI	is	not	indicative	of	an	aetiological	cause	of	their	admission	but	the	lack	of	VTs	in	carriage	would	mean	
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these	types	are	no	longer	circulating	in	the	population	to	cause	disease	(20).	This	in	 conjunction	 with	 their	 admission	 to	 a	 health	 centre	 makes	 them	 an	 ideal	population	to	conduct	surveillance	to	monitor	the	effects	of	PCV	in	the	population	(20).	Explicitly	this	is	because	they	are	at	high	risk	of	disease,	they	come	from	the	population	of	interest	and	they	congregate	in	a	health	facility	for	care.			








4.1.	Study	Site	Administratively,	Lao	PDR	is	made	up	of	18	provinces,	each	consisting	of	districts	containing	 numerous	 villages,	 with	 some	 more	 densely	 populated	 districts	containing	up	to	70	villages.	In	terms	of	health	care,	villages	are	serviced	by	their	designated	local	health	centre	or	district	hospital.	If	the	level	of	care	needed	is	not	available	 at	 the	 health	 centre/district	 hospital,	 patients	 are	 referred	 on	 to	 the	Provincial	Hospital.	If	the	level	of	care	is	not	available	at	the	provincial	level	then	they	 are	 further	 referred	 onto	 the	 large	 Central	 Hospitals	 located	 in	 Vientiane	Capital.	Patients	can	also	present	directly	at	their	health	facility	of	choice	without	a	referral.	Universal	free	health	care	is	currently	not	available	in	the	country,	but	is	being	 trialled	 in	 a	 few	 provinces.	 Routine	 immunisations	 are	 free	 to	 all	 eligible	children.			The	 study	was	 conducted	 at	 the	Paediatric	Department	 of	Mahosot	Hospital,	 the	oldest	hospital	in	Lao	PDR,	a	tertiary	referral	central	hospital	servicing	all	ages	and	conditions.	The	majority	of	patients	that	seek	care	there	are	from	Vientiane	Capital	as	 the	 hospital	 is	 located	 in	 the	 city	 centre.	 Patients	 seek	 care	 directly	 at	 the	hospital	or	are	referred	from	smaller	district	hospitals	and	health	centres.			
4.2.	Design	PneuCAPTIVE	was	nested	 in	 a	 larger	 study	on	 the	 aetiology	of	ARI	 conducted	at	Mahosot	Hospital,	in	collaboration	with	the	Lao-Oxford-Mahosot-Wellcome	Trust-Research	 Unit	 (LOMWRU).	 PneuCAPTIVE	 was	 a	 prospective	 cohort	 study	 with	patients	 recruited	 from	 all	 wards	 admitting	 children	 (general	 paediatric	 ward,	paediatric	infectious	disease	ward	and	neonatal/paediatric	intensive	care	unit)	at	Mahosot	Hospital	from	December	2013	to	June	2017.	Due	to	submission	dates	for	this	thesis	the	data	presented	are	from	December	2013	to	July	2016	(inclusive).		
4.3.	Study	Participants	Eligible	 cases	 were	 children	 aged	 2-59	 months	 admitted	 to	 Mahosot	 Hospital	during	the	study	period	with	ARI	defined	as	a	history	of	illness	≤14	days	with	fever	
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or	documented	tympanic	fever	(>38°C)	and	one	or	more	of	dyspnoea	(as	described	by	 the	 patient	 and/or	 study	 doctor),	 cough,	 rhinitis	 and	 abnormal	 pulmonary	auscultatory	 examination.	 Cases	 that	 did	 not	 satisfy	 the	 eligibility	 criteria	 were	excluded.		Once	 the	 case	was	 deemed	 eligible,	 study	 staff,	 using	 an	 information	 sheet	 as	 a	guide,	explained	the	study	to	the	parent/guardian	of	the	case	for	informed	consent.	The	 signed	 consent	 form	 was	 kept	 with	 the	 relevant	 case	 report	 form	 (CRF)	(Appendix	A)	for	each	case.	It	was	made	clear	to	the	parent	that	at	any	time,	they	could	 rescind	 consent,	 removing	 their	 child	 from	 the	 study.	 Enrolled	 cases	were	allocated	a	unique	study	identification	number.		
4.4.	Data	and	swab	collection	
4.4.1.	Data	collection	Data	were	 collected	 from	 eligible	 cases	 on	 a	 dedicated	 study	 CRF	 (Appendix	 A).	Data	of	interest	collected	included,	village,	sex,	ethnicity,	vaccination	status,	clinical	signs,	symptoms	and	management.	Other	potential	risk	factors	were	also	collected	and	these	included	if	there	was	a	smoker	present	in	the	house,	how	many	children	lived	in	the	house	under	the	age	of	4	years,	financially	self-sufficient,	practised	hot	bed	after	birth,	breastfed	and	if	the	child	attended	kindergarten/day	care.	




		The	 swab	 was	 then	 removed	 and	 immersed	 immediately	 into	 a	 1.0ml	 cryovial	containing	 sterile	 skim	 milk-tryptone-glucose-glycerol	 broth	 (STGGB)	 as	 per	standard	 methods	 (32).	 The	 NPS	 was	 kept	 cool	 and	 transported	 to	 LOMWRU	laboratories	within	4	hours	of	collection,	where	it	was	snap	frozen	at	-80°C.			
4.5.	Lab	methods	Nasopharyngeal	samples	were	shipped	in	batches	on	dry	ice	to	the	Pneumococcal	Research	Group	laboratories	in	the	Murdoch	Childrens	Research	Institute	(MCRI),	Melbourne	for	microbiology	and	microarray	analyses.	At	MCRI,	aliquots	of	NPS	had	DNA	 extracted	 and	 the	 DNA	 eluent	 was	 used	 to	 detect	 the	 presence	 of	pneumococcus	 in	 the	samples	using	a	quantitative	PCR	(qPCR)	method	 targeting	the	 lytA	 gene	 (33,	 34).	 Samples	 positive	 for	 lytA	 or	 equivocal	 were	 grown	 on	selective	nutrient	media	to	not	only	increase	the	quantity	of	DNA	present	but	also	to	 check	 if	 those	 equivocal	 have	 pneumococcus	 in	 the	 samples.	 Equivocals	were	defined	as	samples	with	at	least	1	triplicate	within	the	<40	cycling	threshold	(Ct)	limit.	 Culture	 positive	 samples	 subsequently	 underwent	 DNA	 extraction	 and	analysed	using	a	molecular	serotyping	method,	microarray	(34).	The	microarray,	for	 the	 purposes	 of	 this	 study,	 elucidated	 what	 serotypes	 were	 present	 in	 the	sample	in	rank	order	of	the	most	abundant.	Samples	that	were	culture	negative	but	were	 positive	 for	 lytA	 if	 2/3	 triplicates	 gave	 a	 positive	 result	 (<40	 Ct)	 were	classified	as	positive	for	pneumococcal	carriage	(33,	34).		
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4.6.	PCV	vaccination	status	PCV	 vaccination	 status	 was	 determined	 by	 written	 record	 from	 the	 parent-held	mother	child	health	(MCH)	card	or	the	immunisation	register	at	the	health	centre.	If	the	child’s	record	of	vaccination	was	not	found	at	the	health	centre	and	the	MCH	card	 was	 still	 not	 available,	 any	 child	 satisfying	 the	 criteria	 of	 being	 born	 18	months	prior	to	PCV13	introduction	into	their	village,	receiving	their	vaccinations	in	Thailand/Vietnam	or	 their	parents	 reported	 that	 the	 child	had	never	 received	any	 vaccinations,	 were	 considered	 unvaccinated.	 Figure	 6	 below,	 details	 the	decision-making	flowchart	of	each	case’s	PCV	vaccination	status.		When	 the	 date	 of	 PCV	 vaccinations	 was	 not	 legible	 or	 illogical	 the	 following	assumptions	were	made:	
• Date	of	birth	(DOB)	was	crosschecked	with	date	of	hepatitis	B	vaccination	as	this	was	given	at,	or	shortly	after	birth	to	check	if	DOB	was	correct	
• PCV	dates	were	compared	with	oral	polio	vaccine	and	pentavalent	vaccine	dates,	as	these	three	vaccinations	should	have	been	given	at	the	same	time	to	check	if	the	PCV	dates	were	correct	






4.7.1.	Data	management	Data	 collected	 from	 each	 case	 using	 the	 dedicated	 CRF	were	 first	monitored	 for	correctness	 and	 completeness	 before	 being	 entered	 into	 dedicated	 databases.	Errors	 fixed	on	 the	CRF	had	 the	error	struck	 through	with	a	 line	and	 the	correct	information	noted	above	with	the	initials	of	the	person	making	the	change	and	the	date	 in	 brackets.	 Collected	 data	 were	 double	 data	 entered	 by	 study	 staff	 into	 a	
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Microsoft	Access	database	(Microsoft,	US).	Data	was	cleaned	by	comparing	the	two	entries	and	corrected	in	the	data	entry	database	with	the	discrepancy.	Data	were	extracted	 from	 the	database	 and	 imported	 into	 Stata	14	 IC	 (Statcorp,	US)	where	analysis	was	done.		
4.7.2.	Sample	size	We	expected	there	to	be	a	50%	reduction	in	VT	carriage	in	undervaccinated	cases.	To	 see	 this	 effect	 size,	 400	 cases	were	 estimated	 to	 be	 required	 each	 year	 for	 3	years.	However,	 the	NP	 carriage	 (case)	 population	 sample	 size	was	 restricted	 to	the	 number	 of	 patients	 being	 admitted	 with	 ARI	 or	 pneumonia	 over	 the	 3-year	study	period.	As	we	were	capturing	all	ARI	cases	admitted	to	Mahosot	hospital	in	the	 2-59	 month	 age	 group,	 we	 were	 sampling	 the	 entire	 population	 for	 our	definition,	 thus	we	 could	 not	 improve	 our	 recruitment	methods	 for	 the	 study	 to	attain	the	estimated	annual	400	required.	
4.7.3.	Outcome	variables	
PCV	vaccination	status	The	 number	 of	 PCV13	 doses	 required	 for	 a	 classification	 of	 being	 “vaccinated”	depended	 on	 the	 child’s	 age	 at	 the	 time	 of	 vaccination	 and	 is	 defined	 below	 in	Table	 1	 (35).	 Age	was	 calculated	 by	 the	 child’s	 date	 of	 birth	 and	 the	 time	when	receiving	the	first	dose	of	PCV13.		
	
Table	1:	Classification	of	PCV13	vaccination	status	by	age	and	number	of	doses	
Age	 Vaccinated	 Undervaccinated	0-11	months	of	age	 2	PCV13	doses	 0	or	1	PCV13	dose	≥	12	months	of	age	 1	PCV13	dose	 0	doses	PCV13	PCV13=13-valent	pneumococcal	conjugate	vaccine		




Pneumonia	Definition	 of	 pneumonia	 was	 defined	 according	 to	 the	 2005	 WHO	 Integrated	Management	of	Childhood	Illness	(IMCI)	guidelines.	Using	the	2005	case	definition	for	pneumonia,	the	presence	of	cough	or	difficulty	breathing	and	tachypnoea	(>50	breaths	 per	minute	 for	 children	 aged	 2-11	months;	 >40	 breaths	 per	minute	 for	children	 aged	 12-59	 months)	 plus	 lower	 chest	 wall	 in-drawing	 or	 one	 or	 more	general	danger	signs:	inability	to	drink,	persistent	vomiting,	convulsions,	lethargy,	unconsciousness,	 stridor	when	 calm,	 severe	malnutrition	 (as	 documented	 in	 the	medical	records),	central	cyanosis	or	the	saturation	of	oxygen	<90%	in	room	air.		
Potential	risk	factors	Potential	 risk	 factors	 and	 confounders	 for	 carriage	 rate	 were	 self-reported.	 The	variables	included	in	this	analysis	were	if	there	was	a	smoker	in	the	house,	if	there	were	 children	 <5	 years	 of	 age	 living	 in	 the	 house	 (including	 the	 number),	 if	 the	household	was	financially	self-sufficient,	 if	the	case	was	breastfed	and	if	the	child	attended	kindergarten/day	care.			The	 variables	 were	 yes/no	 dichotomous	 responses,	 except	 for	 the	 number	 of	children	 <5	 years	 of	 age	 living	 in	 the	 house.	 For	 this	 variable,	 the	 presence	 of	children	 <5	 years	 of	 age	was	 analysed	 and	 the	 number	 of	 children	 living	 in	 the	house	 was	 grouped,	 with	 one	 group	 having	 1-2	 and	 the	 other	 greater	 than	 2	children	<5	years	of	age	living	in	the	house.	
4.7.4.	Analysis	In	 general,	 continuous	 variables	 were	 summarised	 using	 the	 number	 of	observations,	minimum	and	maximum,	and	 the	mean	and	standard	deviation	(or	median	 and	 interquartile	 range	 for	 non-parametric	 data).	 Categorical	 variables	were	summarised	using	frequency	counts	and	percentages.			For	 descriptive	 analysis	 of	 the	 cases,	 stratified	 by	 PCV13	vaccinated/undervaccinated,	p-values	using	 the	chi-squared	 test	and/or	95%	CIs	
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were	 calculated	 for	 both	 vaccinated	 and	 undervaccinated	 cases	 to	 determine	 if	there	were	any	significant	differences	between	the	two	groups.		To	observe	the	direct	and	indirect	effects	of	PCV	coverage	and	monthly	VT	carriage	rates	 of	 vaccinated/undervaccinated	 cases	 were	 plotted	 in	 rolling	 7-month	intervals,	overlaid	with	the	monthly	PCV	vaccination	rate	of	all	cases	over	the	time	of	the	study.	Monthly	pneumococcal	carriage	rates	among	cases	was	calculated	by	adding	 the	 number	 of	 cases	 carrying	 a	VT,	 divided	 by	 the	 total	 number	 of	 cases	carrying	any	pneumococcus.	Monthly	vaccination	rate	 in	cases	was	calculated	by	adding	the	number	of	cases	deemed	vaccinated	as	per	the	definition	above,	divided	by	the	total	number	of	cases	enrolled	for	the	month.	Rolling	intervals	were	used	to	smooth	 the	 data	 caused	 by	 the	 small	 numbers	 per	month	 enrolled	 in	 the	 study.	Rolling	intervals	were	calculated	by	plotting	the	average	proportion	of	carriage	or	vaccination	for	the	month	and	the	3	months	before	and	3	months	after	each	month.	Thus	producing	7	month	rolling	intervals	for	each	month	from	December	2013	to	July	 2016.	 For	 both	 monthly	 carriage	 and	 vaccination	 rate	 in	 cases,	 the	 95%	confidence	 intervals	were	 calculated.	 Reported	 carriage	 rates	were	 not	 adjusted	for	potential	confounders	such	as	age	and	seasonality	due	to	time	constraints.		Using	 the	unadjusted	VT	 carriage	 rates,	 it	was	determined	 if	 indirect	 effects	had	occurred	during	the	study.	Maximal	indirect	effects	were	defined	as	the	risk	of	VT	carriage	among	undervaccinated	children	being	equivalent	to	vaccinated	children	2-59	months	of	age,	 i.e.	 a	 risk	 ratio	of	1.	This	 indirect	effect	was	chosen	because	there	 is	 no	 pre-PCV	 data	 available	 to	 calculate	 indirect	 effects	 using	 more	traditional	 methods	 comparing	 post-PCV	 carriage	 rates	 among	 undervaccinated	groups	with	pre-PCV	carriage	rates.			
4.8.	Ethical	considerations	Any	identifying	 information	collected	on	CRFs	were	kept	 in	 locked	filing	cabinets	only	accessible	by	study	staff.	This	was	also	the	case	for	electronic	databases	kept	in	password	protected	drives,	accessible	to	study	staff	only.	In	addition,	letters	of	approvals	 to	 visit	 and	 access	 data	 from	Mahosot	Hospital,	 District	Hospitals	 and	Health	 Centres	 were	 obtained	 from	 both	 the	 director	 of	 Mahosot	 Hospital	 and	LOMWRU	where	the	study	is	based.		
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5.1.	Characteristics	of	cases	In	 total	800	 cases	were	 recruited	 from	December	2013	until	 July	2016.	Of	 those	800,	1	case	was	ineligible,	6	cases	were	missing	data	and	10	were	outside	of	the	2-59	month	age	limits.	Thus	783	cases	were	included	in	the	final	analysis	(Figure	7).			
Figure	7:	Recruitment	flowchart	of	study	up	to	July	2016	























0.56		 0.11	Self-sufficient,	n	(%)	 726	(93)	 306	(92)	 329	(94)	 91	(90)	 0.17	Breastfed,	n	(%)	 461	(59)	 212	(64)	 174	(50)	 75	(74)	 <0.001*	Kindergarten/day	care	attendance,		n	(%)	 149	(19)	 54	(16)	 87	(25)	 8	(8)	 <0.001*	VC	=	Vientiane	Capital		
5.2.	Pneumococcal	carriage	Carriage	samples	were	available	for	all	783	of	cases	included	in	the	final	analysis.	Table	3	below	reports	the	total,	VT,	NVT	carriage	in	cases,	stratified	by	vaccination	status.	The	proportion	of	total	pneumococcal	carriage	was	40%,	with	no	significant	difference	 in	 vaccinated	 and	 undervaccinated	 cases	 (p=0.35).	 Overall	 vaccinated	cases	were	less	likely	to	carry	a	VT	(p<0.001)	and	more	likely	to	carry	a	NVT	than	undervaccinated	 cases	 (p=0.006).	 The	 unknown	 vaccination	 cases	 had	 similar	overall	 carriage,	 but	 when	 comparing	 VT	 and	 NVT,	 the	 proportion	 carried	 was	approximately	equal.			
Table	 3:	 Pneumococcal	 carriage	 in	 ARI	 cases	 admitted	 to	 Mahosot	 Hospital,	 Vientiane	Capital,	Lao	PDR	from	December	2013	to	July	2016,	stratified	by	vaccination	status	
Pneumococcal	
Carriage	 Total	(n=783)	 Vaccinated	(n=331)	 Undervaccinated	(n=351)	 Unknown	(n=101)	 p-value	Total,	n	(%)*	 313	(40)	 126	(38)	 150	(43)	 37	(37)	 0.35	VT,	n	(%)**		 141	(18)	 45	(14)	 78	(22)	 18	(18)	 0.001*	NVT,	n	(%)**	 153	(20)	 78	(24)	 59	(17)	 16	(16)	 0.006*	VT	=	Vaccine	type;	NVT	=	non-vaccine	type	*42	pneumococcal	carriage	positive	samples	did	not	have	a	serotype	or	non-typeable	identified	**Samples	can	contain	multiple	serotypes;	both	VT	and	NVT		






	 	The	 red	 line	 is	 the	 vaccination	 rate;	 blue	 lines	 are	 vaccine	 type	 (VT)	 carriage.	 The	 shaded	 areas	 are	 the	 95%	CI	 surrounding	 carriage	 and	vaccination	rate	
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6.	Discussion	This	 is	 the	 first	 study	 to	 assess	 herd	 immunity	 using	 carriage	 surveillance.	 The	observed	 magnitude	 of	 indirect	 effects	 due	 to	 PCV	 is	 dependent	 on	 a	 range	 of	factors	 such	 as	 the	 immunisation	 strategy,	 coverage	 rate,	 the	 pneumococcal	population	epidemiology	and	 the	quality	of	 surveillance	methods	 to	detect	 these	effects	 (36).	 This	 study	 established	 robust	 surveillance	 at	 Mahosot	 Hospital,	allowing	for	indirect	effects	to	be	observed	in	this	population.			As	per	WHO	recommendations,	 Lao	PDR	uses	 a	3+0	 schedule.	This	 schedule	has	been	 shown	 to	have	 indirect	 effects	on	VT	 IPD	when	 introduced	nationally	 (37),	supporting	 WHO	 recommendations	 for	 the	 advocacy	 of	 these	 lower	 dose	schedules.	 However,	 immunisation	 coverage	 and	 the	 inclusion	 of	 a	 catch-up	campaign	play	larger	roles	in	terms	of	producing	indirect	effects.	Loo	et	al.	(2014	found	 only	 2	 studies	 of	 21	 that	 showed	 no	 evidence	 of	 VT	 IPD	 reductions	 in	unimmunised	 groups	 in	 their	 systematic	 analysis	 of	 indirect	 effects	 of	 dosing	schedules	on	pneumococcal	disease	and	colonisation.	Both	of	 these	studies	came	from	countries	that	did	not	employ	catch-up	campaigns	and	had	vaccine	coverage	levels	 that	 may	 have	 been	 inadequate	 to	 demonstrate	 indirect	 effects	 (37).	 The	method	 by	which	 a	 catch-up	 campaign	 speeds	 up	 the	 process	 of	 indirect	 effects	due	 to	 PCV	 is	 through	 reduction	 of	 NP	 carriage	 of	 VTs	 in	 toddlers	 who	 are	 the	major	reservoir	for	VT	transmission	to	unvaccinated	and	undervaccinated	groups.	Even	though	Lao	PDR	did	 include	a	catch-up	campaign,	allowing	for	PCV13	to	be	given	to	children	up	to	12months	of	age,	this	was	a	passive	system	and	relied	on	children	being	brought	 to	 the	health	 centre	who	had	previously	 completed	 their	vaccinations.	 Thus	 uptake	 would	 have	 been	 minimal	 in	 this	 older	 age	 group,	allowing	 for	 continual	 circulation	 of	 VTs	 in	 the	 community.	 The	 data	 presented	here	 are	 only	 up	 to	 2.5	 years	 post-PCV	 introduction.	 If	 VT	 carriage	 was	 to	 be	interrupted	 in	 the	 community	 it	 would	 require	 vaccination	 of	 5	 birth	 cohorts,	taking	at	least	4	years	to	achieve,	delaying	indirect	effects,	which	would	have	been	created	rapidly	by	an	effective	catch-up	campaign.		The	vaccination	rate	in	cases	increased	over	time	to	reach	70%	by	July	2016.	Based	on	 the	 studies	 by	 Grant	 et	 al.	 (2016)	 and	 Loughlin	 et	 al.	 (2014),	 the	 coverage	
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required	 to	 see	 herd	 immunity	 effects	 based	 on	 VT	 carriage	 in	 the	 <5	 year	 old	population	sat	at	approximately	60-70%	(27,	28).	With	 the	case	vaccination	rate	reaching	 the	60-70%	mark,	herd	 immunity	was	not	expected	as	yet	because	 this	was	the	case	PCV13	vaccination	rate.	The	case	vaccination	rate	is	not	an	accurate	representation	 of	 the	 true	 PCV13	 coverage	 in	 the	 population.	 Firstly,	 the	vaccination	rate	is	based	on	cases	that	have	been	admitted	to	hospital	and	as	cases	are	young,	they	are	not	representative	of	the	community	coverage	for	total	<5	year	olds.	 Secondly,	 even	 though	PCV13	was	 introduced	 into	 routine	 immunisation	 in	October	 2013,	 roll	 out	 of	 PCV13	 has	 been	 gradual,	 with	 some	 of	 the	 further	provinces	not	administering	PCV13	until	 as	 late	as	2015	(pers.	 comm.	Provincial	Health	centre	staff).	This	anecdotal	evidence	is	supported	by	the	undervaccinated	cases	significantly	more	likely	to	come	from	the	provinces.	This	means	that	in	the	wider	community,	PCV13	has	only	been	in	use	for	over	a	year,	contributing	to	the	lack	 of	 herd	 immunity	 effects.	 Thus	 the	 vaccination	 rate	 in	 cases	 is	 likely	 an	overestimation	of	the	true	coverage	in	the	community.			Mature	 PCV	 programmes	 see	 a	 greater	 impact	 of	 PCV	 than	 new	 adopters	 (13).		Previous	studies	by	Loughlin	et	al.	(2014)	and	Grant	et	al.	(2016)	were	undertaken	in	settings	where	PCV7	had	been	in	use	for	many	years,	so	therefore	the	coverage	they	 estimated	 for	 PCV	 herd	 immunity	was	 based	 on	 the	 additional	 6	 serotypes	included	 in	 PCV13,	 not	 all	 PCV13	 VTs.	 As	 the	 case	 vaccination	 rate	 is	 likely	 an	overestimation	 of	 the	 true	 community	 coverage,	 other	 methods	 of	 vaccine	coverage	 were	 considered.	 A	 contact	 serosurvey	 was	 conducted	 and	simultaneously	 data	 was	 collected	 from	 immunisation	 registers	 held	 at	 health	centres	 and	 district	 hospitals	 around	 the	 country.	 For	 the	 contact	 serosurvey,	contacts	 of	 cases	 were	 identified	 and	 their	 vaccination	 status	 was	 determined	either	using	MCH	cards	or	health	centre	immunisation	registry	data.	In	addition	a	subset	of	contacts	12-59	months	of	age	had	a	blood	sample	collected	to	determine	their	PCV	vaccination	status.	For	the	immunisation	registry	data,	each	village	keeps	a	record	of	vaccination	at	their	assigned	health	centre	or	district	hospital.	This	data	is	 kept	 in	 a	 line	 list	 format,	 allowing	 each	 child	 to	 be	 counted	 individually.	Amalgamated	with	population	data	for	each,	village,	the	monthly	vaccination	rate	for	 each	 village	 could	 be	 estimated.	 Immunisation	 registry	 data	 was	 collected	dependent	on	the	village	the	case	resided	in.	The	theory	behind	both	methods	was	
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that	 carriage	 was	 affected	 most	 by	 children	 they	 have	 contact	 with.	 Based	 on	preliminary	 data	 from	 the	 contact	 serosurvey	 (data	 not	 shown),	 the	 vaccine	coverage	rate	did	not	correspond	to	 the	preliminary	data	(data	not	shown)	 from	the	 health	 centre	 immunisation	 registry.	 Therefore,	 it	 was	 decided	 the	 contact	serosurvey	did	not	provide	an	accurate	estimate	of	community	coverage	and	was	suspended.	 Data	 collection	 and	 analysis	 will	 be	 pursued	 for	 the	 health	 centre	immunisation	 registries	 as	 the	 primary	 method	 for	 estimating	 community	coverage	in	the	final	analysis.			Vaccinated	 cases	 had	 significantly	 lower	 carriage	 of	 VTs	 than	 undervaccinated	cases,	 but	 total	 pneumococcal	 carriage	 rates	 did	 not	 change	 for	 both	 groups.	Pneumococcal	carriage	rates	are	affected	by	age,	seasonality,	risk	 factors	and	the	presence	of	NVTs.	Carriage	rates	are	associated	with	age,	with	peak	carriage	rates	in	toddlers	and	wane	over	time	(38-40).	As	cases	of	ARI	admitted	to	hospital	are	in	younger	age	groups,	most	of	 these	will	be	vaccinated	 in	comparison	 to	 the	older	children	in	the	early	years	of	PCV	introduction.	Over	time,	the	percentage	of	older	children	 entering	 the	 surveillance	 who	 are	 vaccinated	 will	 increase	 as	 multiple	birth	 cohorts	 are	PCV13	vaccinated.	 In	 addition,	 the	decline	 in	VT	 in	 early	 years	post	 PCV	 may	 purely	 be	 due	 to	 the	 fact	 older	 children	 have	 less	 carriage	 and	subsequently	less	likely	to	carry	VTs.	Therefore	carriage	rates	need	to	be	adjusted	for	age.	Carriage	is	also	affected	by	season	with	winter	in	temperate	climates	and	dry	 season	 in	 tropical	 climates	 seeing	 peaks	 in	 pneumococcal	 carriage	 (41,	 42).	However,	risk	factors,	such	as	age	and	seasonality	were	not	accounted	for	in	these	results.	 For	 the	 final	 analysis	 risk	 factors	will	 be	 identified	 and	 accounted	 for	 in	both	 carriage	 and	 vaccination	 rates	 in	 cases.	 In	 addition	 to	 age,	 season	 and	PCV	coverage,	 pneumococcal	 carriage	 is	 also	 influenced	 by	 many	 factors	 such	 as	exclusive	 breast-feeding,	 crowding,	 socio-demographic	 information,	 caregiver	education	level,	smokers	in	household	and	kindergarten	attendance	to	name	a	few.	However,	 as	 total	 pneumococcal	 carriage	 did	 not	 change	 over	 the	 study	 period,	these	risk	factors	may	not	have	changed	over	time	and	if	not	accounted	for	will	not	significantly	 change	 the	 results.	 Nonetheless	 potential	 confounders	 will	 be	assessed	 in	 the	 final	 analysis,	 but	 due	 to	 time	 constraints	 it	was	 not	 possible	 to	include	these	adjustments	in	these	results.			
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Replacement	 carriage,	 or	 serotype	 replacement	 has	 been	 seen	 in	 all	 populations	using	 PCVs	 (43).	 Serotype	 replacement	 is	 the	 increase	 of	 NVTs	 among	asymptomatic	carriers	following	reductions	in	VTs	and	to	a	lesser	extent	invasive	disease	 caused	by	NVTs	 (43).	The	potential	 reasons	behind	 this	 increase	 in	NVT	carriage	 after	 use	 of	 PCV	 in	 a	 population	 could	 be	 due	 to	 the	 phenomenon	 of	unmasking,	where	 the	reduction	of	VTs	has	made	 it	easier	 to	detect	NVTs	or	 the	acquisition	 of	 NVTs	 after	 VTs	 are	 removed	 from	 the	 nasopharynx	 (43).	Surveillance	of	NVTs	is	 important	for	a	number	of	reasons,	namely	monitoring	of	NVT	 IPD,	 increasing	 understanding	 of	 serotype	 composition	 in	 a	 population	 and	design	 of	 next	 generation	 PCVs.	 In	 a	 systematic	 review	 and	 meta-analysis	 by	Balsells	 et	 al.	 (2017),	 prior	 to	 the	 introduction	 of	 higher	 valency	 PCVs	 in	 North	America	 and	 Europe,	 approximately	 half	 of	 childhood	 IPD	 cases	 were	 due	 to	serotypes	 not	 incorporated	 in	 current	 PCV	 formulations	 (44).	 Asia,	 where	 the	largest	 burden	of	 disease	 lies	 also	has	 a	 great	diversity	 of	 serotypes	 (18),	which	has	repercussions	in	how	effective	current	formulation	PCVs	will	be.	Development	of	 next	 generation	 PCVs	 will	 require	 more	 data	 from	 LMICs	 regarding	 NVTs	 to	create	vaccine	formulations	that	will	afford	greater	protection.			In	conclusion,	less	than	3	years	after	PCV13	introduction,	herd	immunity	effects	of	PCV13	based	on	NP	carriage	surveillance	in	ARI	cases	has	not	yet	been	observed	in	Lao	PDR.	This	is	not	unexpected,	as	PCV13	coverage	in	the	community	of	Lao	PDR	is	 likely	 too	 low	 to	 protect	 the	 undervaccinated	 population.	 This	 is	 because	 the	data	are	only	up	 to	2.5	years	post-PCV	 introduction.	However	direct	effects	have	manifested	in	vaccinated	cases,	shown	by	the	reduction	in	VTs,	with	no	change	in	total	pneumococcal	 carriage	 rates	 for	 all	 cases.	The	data	presented	has	not	been	adjusted	for	confounders.	Data	on	potential	confounders	have	been	collected	and	will	 be	 included	 in	 the	 final	 analysis.	 The	 data	 presented	 here	 shows	 the	applicability	of	NP	surveillance	in	ARI	cases	as	a	method	to	determine	when	a	PCV	program	has	 achieved	herd	 immunity	 effects	 for	 their	population.	This	 is	 crucial	for	 LMICs	 like	 Lao	 PDR,	 who	 are	 unable	 to	 rely	 on	 typical	 methods	 of	 PCV	evaluation.	 The	method	presented	 here	 shows	 that	 a	 robust	 surveillance	 system	can	be	established	quickly	in	a	LMIC	setting.	These	data	will	strengthen	the	use	of	this	method	in	other	LMICs	in	the	region	considering	using	PCV	in	their	population.	Lao	PDR	 is	expected	 to	 transition	 to	a	domestic	 funding	model	 for	 their	NIP	and	
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• Continuation	of	NP	carriage	surveillance	should	continue	to	determine	the	coverage	required	to	see	indirect	effects.	The	primary	aim	of	the	study	has	not	 been	 achieved	 as	 yet.	 Once	 indirect	 effects	 have	 been	 observed,	 the	corresponding	 coverage	 will	 set	 a	 minimum	 benchmark	 for	 NIP	 Laos	 to	reach	in	order	to	get	the	maximal	benefit	from	PCV	for	their	population.	
• Estimation	of	coverage	was	part	of	 the	primary	aim	for	 this	study.	During	the	time	of	the	study,	PCV13	coverage	was	not	able	to	be	included	in	the	EPI	coverage	 survey.	 In	 addition	 to	 calculating	 vaccination	 rates	 in	 cases,	vaccine	 coverage	 was	 also	 assessed	 using	 a	 contact	 serosurvey	 and	 raw	data	 collected	 from	 the	 village	 immunisation	 registers	 held	 at	 health	centres	and	district	hospitals	throughout	the	country.	Based	on	preliminary	analysis,	 the	 contact	 serosurvey	 was	 not	 a	 good	 measure	 to	 estimate	vaccine	 coverage.	 Therefore,	 it	 is	 recommended	 to	 continue	 collection	 of	immunisation	data	from	health	centres	and	district	hospitals	and	to	use	this	method	to	estimate	vaccine	coverage.			
• Surveillance	of	serotype	carriage	should	continue	to	monitor	 the	situation	with	NVTs.	Not	all	serotypes	cause	disease	but	the	elimination	of	VTs	from	carriage	creates	an	opportunity	 for	other	serotypes	 to	occupy	 the	vacated	space	 and	 potentially	 cause	 IPD.	 These	 replacement	 serotypes	 are	important,	as	 it	will	advise	 the	 future	PCV	 formulations	or	 the	design	of	a	vaccine	that	targets	a	shared	antigen	irrespective	of	serotype.		
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1.1.	Role	A/Prof	 Fiona	 Russell	 was	 contracted	 by	 the	 World	 Health	 Organization	 (WHO)	Western	Pacific	Regional	Office	(WPRO)	to	conduct	an	evaluation	of	rotavirus	(RV)	vaccine	introduction	in	Kiribati.	This	was	to	support	the	introduction	of	RV	vaccine	into	the	Kiribati	national	expanded	program	of	immunisation	(EPI)	schedule.	The	terms	of	 reference	 for	 this	work	was	 to	 establish	 post-marketing	 surveillance	 of	intussusception	 (IS)	 and	 also	 a	 establish	 burden	 measurement	 of	 acute	gastroenteritis	(AGE)	that	could	be	used	to	evaluate	the	impact	of	RV	vaccine	in	the	community.		With	the	assistance	and	guidance	of	A/Prof	Russell,	my	role	was	to	complete	the	terms	of	reference	set	by	WHO	WPRO	for	evaluating	RV	vaccine	introduction	into	Kiribati.	The	evaluation	consisted	of	2	parts:	1)	determining	baseline	data	for	AGE,	IS	 and	 severe	 acute	malnutrition	 (SAM)	 and	 2)	 designing	 and	 establishing	 an	 IS	surveillance	 system	 as	 part	 of	 RV	 vaccine	 post-marketing	 surveillance	 of	 IS.	 To	achieve	this	I	was	responsible	for:	
• Drafting	of	a	protocol	 to	detail	our	methods	 for	 the	evaluation	before	our	site	visit	
• Preparing	 all	 data	 collection	 instruments,	 adapted	 from	 WHO	 generic	protocols	for	RV	vaccine	introduction	(included	in	Appendix	A	and	C)	
• Liaising	with	Ministry	of	Health	and	Medical	Services	(MHMS)	staff	to	find	and	access	the	required	data	
• Where	available,	reviewing	and	cleaning	electronic	hospital	admission	data	
• Going	 through	 hospital	 admission	 books	 where	 electronic	 data	 were	 not	available	
• Cleaning	and	subsequently	analysing	the	data	for	reporting	
• Presentation	 of	 preliminary	 results	 and	 methods	 of	 continual	 IS	surveillance	to	MHMS	and	Tungaru	Central	Hospital	(TCH)	paediatric	staff	




Specifically	 for	 IS	 surveillance,	 I	 was	 responsible	 for	 writing	 the	 standard	operating	 procedure	 (SOP),	 training	 the	 local	 coordinator	 and	 acting	 as	 the	external	monitor	to	support	and	monitor	the	surveillance.	 I	plan	to	return	in	 late	2017	 to	 complete	 the	 evaluation	 and	 collect	 any	missing	data	 from	 the	previous	site	visit.	With	the	approval	 from	WPRO	and	MHMS,	a	manuscript	describing	the	baseline	AGE	and	SAM	incidence	prior	to	RV	vaccine	introduction	was	prepared	for	submission	to	Western	Pacific	Surveillance	and	Response	Journal	(WPSAR).			In	 addition	 during	my	 time	 on	 site,	 I	 assisted	 in	 a	 limited	 capacity	with	 an	 AGE	outbreak	and	subsequently	acute	respiratory	infection	outbreak	in	Tarawa.	During	these	 outbreaks	 I	 acted	 in	 an	 informal	 capacity	 to	 help	 staff	 at	 TCH	 with	 case	reporting	 and	 I	 also	 liaised	with	 the	different	departments	 (statistics,	 laboratory	and	 environmental	 unit)	 involved	 to	 check	 on	 the	 progress	 of	 the	 outbreak	investigation.	 	This	experience	was	my	first	opportunity	to	apply	classroom	skills	in	 outbreak	 investigation	 to	 a	 real	 life	 setting.	 After	 effective	 public	 health	interventions	promoting	hygiene	practises	in	the	community	the	outbreaks	ceased	after	a	few	days	with	a	limited	number	of	cases.		


















Background	 and	 Aims:	 Rotavirus	 (RV)	 is	 the	 most	 common	 cause	 of	 acute	gastroenteritis	(AGE)	in	infants	and	children	globally.	To	address	the	high	burden	of	AGE	in	Kiribati,	the	Ministry	of	Health	and	Medical	Services	(MHMS)	introduced	RV	vaccine	 in	August	2015.	As	part	of	RV	vaccine	 introduction,	 the	World	Health	Organization	 (WHO)	 recommends	 post-marketing	 safety	 surveillance	 of	intussusception	(IS).	IS	is	a	rare,	but	severe,	adverse	event	shown	to	be	associated	with	RV	vaccine	use.	Thus	 to	 support	 the	 introduction	of	RV	vaccine,	baseline	 IS	incidence	 and	 epidemiology	 was	 determined	 and	 active	 surveillance	 of	 IS	 was	established	 to	 ascertain	 if	 there	 was	 a	 temporal	 relationship	 of	 IS	 cases	 to	 RV	vaccine	as	part	of	recommended	post-marketing	safety	monitoring.	
	
Methods:	 To	 determine	 baseline	 IS	 incidence	 and	 epidemiology,	 data	 were	collected	 for	children	<2	years	admitted	 to	Tungaru	Central	Hospital	 (TCH)	 from	June	2010	 to	April	2015.	Eligibility	 criteria	 for	 IS	 cases	was	 children	≤24months	with	 a	 discharge	 diagnosis	 of	 IS	 or	 bowel	 obstruction.	 To	 ensure	 no	 cases	were	missed,	deaths	associated	with	dysentery	or	bloody	diarrhoea	were	also	searched	for	as	a	common	symptom	of	IS	is	red	currant	stools.	Medical	records	of	potential	IS	 cases	 were	 reviewed	 and	 IS	 was	 confirmed	 if	 they	 satisfied	 Level	 1	 of	 the	Brighton	 clinical	 case	 definition.	 In	 addition,	 confirmed	 cases	 had	 sex,	 age,	residence,	date	of	admission,	date	of	discharge,	discharge	diagnosis,	management	and	 outcome	 (alive/dead),	 extracted	 from	 the	 medical	 records,	 to	 describe	 the	epidemiology	of	cases	during	the	study	period.	The	2010	Census	data	for	Tarawa	was	used	as	the	denominator	to	calculate	IS	incidence.	To	establish	IS	surveillance	post-RV	 vaccine	 introduction	 in	 August	 2015,	 cases	with	 diagnoses	 indicative	 of	bowel	 obstruction	 and	 admitted	 to	 TCH,	 were	 eligible	 for	 inclusion.	 A	 temporal	relationship	to	RV	vaccine	was	determined	by	an	IS	event	occurring	1-7	days	after	the	 first	dose	of	RV	vaccine	or	 likely	 related	8-21	days	after	 the	 first	dose	of	RV	vaccine	or	1-7	days	after	the	second	dose	of	RV	vaccine.	
	































of	vaccine	(multiplicity-adjusted,	relative	risk	1.6;	95%	CI	0.4-6.2)	(15).	Therefore	like	RotaTeq®,	Rotarix®	in	this	trial	setting,	was	not	found	to	have	a	significantly	increased	risk	of	IS	in	vaccine	recipients	at	any	time	during	the	study	period	(15).				From	 pre-licensure	 data,	 both	 vaccines	 were	 highly	 efficacious	 against	 many	different	 types	 of	 RV	 genotypes,	 making	 them	 highly	 appealing	 to	 all	 countries	with	 a	 high	 burden	 of	 RV	 disease.	 Vaccine	 efficacy	 of	 84.7%	 and	 98%	 against	severe	RV	gastroenteritis	was	observed	 for	RotaTeq®	and	Rotarix®	respectively	(15,	16).	Thus	both	RV	vaccines	were	shown	to	not	only	be	efficacious	against	RV	disease	 but	 also	 demonstrated	 safety	 with	 IS	 as	 an	 outcome,	 leading	 to	 their	successful	licensure.			




and	 hospitalisations	 of	 AGE	 outweigh	 the	 risk	 of	 IS,	 WHO	 recommends	 post-marketing	 surveillance	 should	 be	 conducted	 for	 severe	 adverse	 events,	 with	 a	focus	on	 IS	whenever	RV	vaccines	are	 introduced	 into	new	populations	 (4).	This	has	 been	 supported	 by	 WHO	 with	 standardised	 guidelines	 on	 how	 to	 conduct	surveillance	 and	 data	 collection	 forms	 to	 collect	 pre-	 and	 post-RV	 vaccine	introduction	in	a	given	population	(1).		Post-marketing	surveillance	of	RV	vaccine	can	be	done	actively,	passively	or	using	a	combination	of	both	methods.	In	an	active	system,	the	options	include	an	active	search	for	adverse	reactions	or	active	follow	up	of	vaccine	recipients	for	a	defined	period	of	time.	The	benefits	of	an	active	system	are	that	data	are	collected	in	real-time,	 collected	 data	 are	 the	 most	 accurate	 and	 specific	 research	 questions	regarding	vaccine	effectiveness	or	potential	adverse	events	can	be	addressed	(7).	The	 disadvantages	 of	 an	 active	 system	 are	 that	 it	 is	 more	 labour	 intensive	 and	costly.	Passive	systems	are	reliant	on	reporting	 from	stakeholders	 in	 the	system.	The	 benefits	 of	 a	 passive	 system	 are	 the	 use	 of	 existing	 resources.	 The	disadvantages	 of	 a	 passive	 system	 are	 the	 reliance	 on	 reporting,	 which	encompasses,	 under-reporting	 of	 adverse	 events,	 incomplete	 data,	 limited	 or	 no	follow	 up,	 unable	 to	 ascertain	 definitive	 diagnoses	 and	 inaccurate/lack	 of	numerator/denominator	 data	 to	 be	 able	 to	 establish	 causality	 or	 incidence	 (7).	Monitoring	 for	 a	 rare	 severe	 adverse	 event	 like	 IS	 can	 be	 achieved	 through	 a	combination	of	both	active	and	passive	systems.	This	minimises	the	disadvantages	in	both	systems.			






• Determine	 a	 baseline	 incidence	 of	 IS	 pre-RV	 vaccine	 introduction	 in	children	≤2years	of	age	living	on	Tarawa	






4.1.	Context	Kiribati	 is	 a	 country	 of	 33	 atolls	 and	 low-lying	 reefs	 widely	 scattered	 along	 the	Equator	 in	 the	 central	 Pacific	 Ocean	 (24).	 Kiribati	 has	 a	 population	 of	approximately	100,000,	with	11,000	of	those	being	children	<5	years	of	age	(24).	The	 island	 of	 Tarawa	 is	 home	 to	 approximately	 60%	 of	 the	 total	 population	 of	Kiribati.	 The	 national	 economy	 depends	 primarily	 on	 I-Kiribati	 people	 working	abroad,	fishing	licence	fees,	exports	of	sea	products	and	foreign	aid	(24).	Kiribati	is	vulnerable	 both	 internally	 due	 to	 depletion	 of	 limited	 natural	 resources	 and	externally	 to	 the	effects	of	 climate	 change	on	 rising	 sea	 levels	 and	unpredictable	weather	 (24).	 Kiribati	 has	 the	 lowest	 level	 of	 development	 in	 the	 Pacific	 region	when	accounting	for	mortality,	morbidity	and	living	conditions	per	capita	GDP	and	also	is	considered	a	least	developed	country	globally	(24).			Each	 village	 in	 Kiribati	 has	 a	 health	 centre	 staffed	 by	 nurses	who	 provide	 basic	primary	health	care,	administer	vaccinations	and	run	health	promotion	activities.	Patients	who	 require	 further	 care	 are	 either	 referred	 or	 seek	 care	 at	 1	 of	 the	 2	hospitals	on	Tarawa:	one	in	Betio	and	the	other,	Tungaru	Central	Hospital	(TCH),	in	Bikenibeu.	TCH	is	the	main	hospital	for	Tarawa	and	also	the	only	facility	that	can	provide	management	for	severe	cases	of	disease	and	provide	surgery.	TCH	is	also	the	referral	hospital	 for	 the	outer	 islands.	The	majority	of	 families	on	Tarawa	do	seek	health	care	at	TCH.	However	it	is	not	uncommon	for	children	to	die	at	home	with	no	autopsy	or	death	reporting	available,	especially	for	children	who	reside	on	the	outer	islands	where	access	to	health	care	is	a	major	issue.			
4.2.	Determining	baseline	IS	incidence	




definition	for	IS	based	solely	on	clinical	criteria	(7).	Using	a	clinical	case	definition	bypassed	 the	 need	 for	 access	 to	 radiological,	 ultrasound	 or	 surgical	 diagnoses,	especially	 in	 regions	where	 these	 facilities	or	expertise	may	not	be	available	 (7).	The	definition	was	suitable	for	use	in	a	wide	range	of	settings	and	provided	a	set	of	standardised	clinical	criteria	validated	in	developed	and	developing	countries	(7).	Quoting	 from	 WHO	 post-marketing	 safety	 surveillance;	 ‘The	 definition	 divides	clinical	events	into	a	classification	according	to	the	level	of	evidence	for	diagnostic	certainty,	with	level	1	diagnostic	certainty	defined	as	a	confirmed	or	definite	case	of	 intussusception”	 (7).	 	However,	WHO	also	recommends	capturing	all	 clinically	suspected	 events,	 regardless	 of	 satisfaction	 of	 the	 Brighton	 Collaboration	 case	definition	(7).			Potential	IS	cases	were	those	aged	≤24	months	old,	and	had	a	discharge	diagnosis	of	IS	or	bowel	obstruction.	In	these	cases	the	medical	records	of	each	potential	case	were	 reviewed	 and	 determined	 to	 be	 a	 Level	 1-3	 case	 of	 IS	 as	 per	 the	 Brighton	clinical	case	definition	by	a	paediatrician	(7,	25).			
Box	1:	Brighton	clinical	case	definition	of	intussusception	
	
4.2.2.	IS	data	collection	Hospital	admission	books	(June	2010-April	2015)	and	electronic	medical	records	were	reviewed	for	potential	IS	cases	in	children	<2years	of	age.	For	the	electronic	data,	 the	 search	 terms	 ‘IS’	 and	 ‘bowel	 obstruction’	 were	 used	 to	 find	 potential	
• Level	1	-	diagnosis	of	IS	by	surgical,	radiological	or	autopsy	criteria;	
• Level	 2	 -	 presence	 of	 2	 major	 clinical	 criteria	 or	 1	 major	 and	 3	 minor	criteria;		




cases.	 Using	 the	 same	 search	 terms,	 hospital	 admission	 books	 were	 manually	searched	for	the	time	periods	electronic	data	was	not	available.	Data	from	January	2014	and	February	2014	were	 incomplete	 from	both	sources.	Both	sources	were	in	a	line	list	format,	inclusive	of	unique	hospital	number.	In	addition,	following	on	from	 concerns	 of	 the	 paediatric	 staff	 of	 potential	 cases	 being	 missed	 with	 the	above	inclusion	criteria,	deaths	caused	by	dysentery	or	had	reported	blood	in	the	stool	were	also	reviewed	as	potential	IS	cases.	To	cross-check	the	list	of	potential	cases	found	was	complete,	we	also	asked	the	paediatricians	and	paediatric	surgeon	if	there	were	any	potential	cases	we	had	missed.		All	potential	IS	cases	had	their	medical	records	reviewed	and	data	were	recorded	on	 a	 dedicated	 data	 collection	 form	 (Appendix	 A).	 Variables	 collected	 from	 the	hospital	 records	 were	 sex,	 age,	 residence,	 date	 of	 admission,	 date	 of	 discharge,	discharge	 diagnosis,	 management	 and	 outcome.	 Based	 on	 clinical	 symptoms	and/or	results	from	investigations,	cases	were	classified	as	a	level	1,	2,	3	using	the	Brighton	 clinical	 case	 definition	 by	 a	 paediatrician.	 All	 completed	 forms	 were	placed	in	a	folder	held	at	the	WHO	country	office.			
4.2.3.	Study	population	For	incidence	calculations,	the	TCH	catchment	population	was	defined	as	children	<2	 years	 residing	 on	 Tarawa.	 Potential	 cases	 residing	 outside	 of	 Tarawa	 were	excluded	after	all	cases	were	identified.	Hence,	only	hospitalised	IS	cases	residing	on	Tarawa	were	included	in	the	population-based	analysis.	Denominator	data	for	rates	were	obtained	from	the	most	recent	census,	which	occurred	in	2010.	The	age	groups	 in	 the	2010	 census	 relevant	 for	 this	 review	were	<12	months	 and	12-23	months.	A	2.2%	growth	 rate	was	 applied	per	 annum	 to	 the	2010	 census	data	 to	calculate	the	2011-2015	<2	years	population.	







4.3.2.	Engaging	stakeholders	The	Ministry	of	Health	and	Medical	Services	in	Kiribati	asked	WHO	to	assist	with	the	 evaluation	 and	 IS	 surveillance	 for	 RV	 vaccine	 introduction.	 Thus	MHMS	was	engaged	 in	 the	 process	 from	 the	 outset.	 We	 had	 a	 series	 of	 meetings	 with	 the	paediatricians	 and	 a	 TCH	 surgeon	 to	 explain	 the	 purpose	 and	 goals	 of	 our	 visit.	During	these	meetings	we	discussed	their	clinical	experience	and	management	of	IS	cases	and	the	number	of	IS	cases	seen	each	year.	In	addition	the	meetings	were	to	 explain	 the	 purpose	 of	 conducting	 IS	 surveillance	 to	 not	 only	 increase	awareness	 of	 IS	 in	 the	 hospital	 but	 also	 to	 identify	 a	 suitable	 staff	member	who	could	conduct	the	surveillance.	






4.3.4.	Available/required	resources	We	 considered	 the	 following	 resources	 that	 would	 be	 required	 for	 system	operation:	data	collection	tools,	method	of	data	storage,	a	local	coordinator	and	a	SOP	 for	 them	 to	 follow.	 Through	discussions	with	 paediatric	 staff,	WHO	 country	office	 and	 MHMS	 we	 considered	 whether	 employing	 a	 local	 coordinator	 from	outside	the	hospital	was	feasible.	However,	the	paediatric	staff	suggested	it	would	be	best	to	ask	a	senior	member	of	staff	to	act	in	this	capacity	as	they	would	be	on	site	and	also	already	knew	the	protocols	at	TCH.			











− Stability	 (ability	 to	 collect,	 manage,	 and	 provide	 data	 properly	 without	failure	and	to	be	operational	when	it	is	needed)		





5.1.	Baseline	IS	incidence	There	were	2	IS	cases	over	the	5-year	period	pre-RV	vaccine	 introduction	(Table	1).	Both	cases	were	female,	aged	5	months	old	and	required	surgical	intervention.	Case	 1	 fully	 recovered	 with	 no	 sequelae	 and	 Case	 2	 recovered	 with	 sequelae,	requiring	further	surgery	for	intestinal	adhesions.	The	annual	incidence	of	IS	was	20	 per	 100,000	 (95%	 CI	 2-73)	 children	 <1	 years.	 In	 addition,	 no	 deaths	 from	dysentery	or	reported	blood	in	stool	met	the	Brighton	IS	classification.		Approximately	3000	infants	will	be	vaccinated	in	Kiribati	each	year.	The	estimated	increased	 risk	 of	 IS	 due	 to	 rotavirus	 vaccine	 is	 2-7	 cases	 per	 100,000	 infants	vaccinated.	 Therefore,	 based	 on	 the	 risk	 calculated	 by	 previous	 studies	 (17,	 18),	there	may	be	one	additional	case	of	 IS	every	5-17	years	 in	Kiribati,	 following	the	introduction	of	RV	vaccine.			
Table	 1:	 Characteristics	 of	 intussusception	 cases	 <2	 years	 admitted	 to	 Tungaru	 Central	Hospital	(TCH),	June	2010-April	2015	
Characteristics	 Case	1	 Case	2	
Age	 5	months	 5	months	Sex	 Female	 Female	Residence		 Bikenibeu	 Betio	Year	of	admission	 2014	 2011	Management	 Surgery	 Surgery	LOS	 3	days	 28	days	Outcome	 Fully	recovered	 Recovered	with	sequelae		
5.2.	IS	Surveillance	




paediatric	 staff,	WHO	 country	 office	 and	MHMS,	we	 decided	 it	would	 be	 best	 to	identify	an	existing	staff	member	to	act	as	the	local	coordinator	for	the	system.	The	local	 coordinator	 would	 absorb	 the	 IS	 surveillance	 role	 into	 their	 pre-existing	duties.		Concerns	were	raised	by	medical	staff	of	the	possibility	of	missed	IS	cases	due	to	misdiagnosis	 of	 IS	 as	 dysentery.	 Thus	we	 also	 included	 a	 review	of	 any	 cases	 of	death	with	 dysentery	 or	 reported	 blood	 in	 stool	 of	 children	 in	 our	 age	 group	 to	ensure	 these	 were	 not	 misdiagnosed	 and	 subsequently	 missed	 in	 our	 system.	Discussions	with	 paediatric	 staff	 at	 TCH	 also	 informed	 our	 understanding	 of	 the	data,	 in	 that	 we	 became	 aware	 that	 surgical	 intervention	 is	 available	 but	ultrasound	reduction	and	air/liquid	enema	are	not	available	and	autopsies	are	not	performed.	


















collection	 forms.	We	wrote	an	SOP	 for	use	as	both	 training	 tool	and	surveillance	protocol	 for	 the	 local	 coordinator	 to	 follow.	 Due	 to	 the	 small	 number	 of	 cases,	paper	 records	 and	 photocopies	 of	 the	 relevant	 medical	 records	 will	 be	 kept	 at	MHMS.		The	 deputy	 nurse	 of	 the	 paediatric	 ward	 was	 assigned	 to	 coordinate	 the	 IS	surveillance	 system	 and	 as	 the	 designated	 local	 IS	 surveillance	 coordinator.	 The	local	coordinator	was	trained	in	the	IS	surveillance	SOP	(Appendix	B)	to	undertake	the	surveillance	at	TCH.			External	monitors	 are	 scheduled	 to	 return	within	 2	 years	 after	 establishment	 of	the	 system	 to	 review	 the	 data	 collected	 in	 the	 system.	 In	 the	 interim,	 external	monitors	were	in	regular	contact	with	the	local	coordinator	to	monitor	cases,	help	with	the	review	of	suspected	cases	remotely	and	also	provide	support	to	the	local	coordinator.	 The	 review	 post-RV	 vaccine	 introduction	 will	 be	 done	 to	 not	 only	ensure	no	cases	have	been	missed	but	also	to	ensure	children	who	have	died	and	have	 a	 discharge	 diagnosis	 of	 dysentery	 or	 bloody	 diarrhoea	 were	 correctly	classified	(see	sensitivity	below).		
5.2.5.	Results	of	the	system	so	far	Rotavirus	 vaccine	was	 introduced	 into	 Kiribati	 in	 August	 2015.	 As	 of	 December	2016,	there	have	been	no	cases	of	IS	reported	by	the	local	coordinator	and	public	health	nurses	in	TCH	and	Kiribati	respectively.		
5.2.6.	Attributes	of	the	IS	surveillance	system	





Flexibility	The	system	is	expected	to	be	 flexible	as	 there	are	very	 limited	components	to	 its	function.	External	monitors	 can	 change	 forms	quickly	with	 advice	 from	 the	 local	coordinator	without	affecting	existing	reporting	or	collection	methods.	This	is	also	true	 of	 inclusion	 of	 other	 adverse	 events	 such	 as	 fever,	 vomiting,	 nausea.	Intussusception	 is	 not	 an	 infectious	 disease	 and	 the	 presentation	 and	 number	cases	 suffering	 from	 IS	will	 not	 change,	 thus	 the	 case	 definition	will	 remain	 the	same	throughout	the	surveillance	period	and	thereafter.	The	main	concern	for	the	systems	 flexibility	would	be	changing	of	associated	health	personnel.	 If	 this	does	happen,	 the	 external	monitor	 will	 liaise	 with	 the	 relevant	 staff	 in	WHO	 country	office	to	identify	suitable	health	personnel	to	take	over.		
Data	quality	To	 address	 the	 issue	 of	 data	 completeness,	 the	 local	 coordinator	will	 photocopy	the	relevant	medical	records	held	either	at	the	bedside	of	the	child	(if	they	haven’t	yet	 been	 discharged)	 or	 from	 the	 medical	 records	 department	 located	 at	 the	hospital.	 The	 local	 coordinator	 will	 also	 have	 access	 to	 the	 treating	paediatrician/surgeon	and	can	discuss	specific	case	issues	and	confirm	a	potential	temporal	relationship	between	the	IS	event	and	RV	vaccination	with	them.	For	RV	vaccination	 status,	 it	 is	 expected	 the	 case’s	 vaccination	 history	 can	 be	 located	 at	their	relevant	clinic.	Also	the	RV	vaccine	batch	and	expiry	will	be	easily	accessible	from	the	MHMS	pharmacy	located	at	the	hospital,	eliminating	the	need	to	travel	for	this	 information.	At	 the	 subsequent	 site	 visit,	 the	 external	monitor	will	 check	 all	the	 completed	 forms	 for	 completeness	 and	 if	 there	 is	 uncertainty,	 consult	 the	photocopied	medical	records	for	the	case.	





Sensitivity	This	system	is	expected	to	be	highly	sensitive	at	both	the	level	of	case	presentation	and	case	diagnosis.	As	IS	is	a	severe	disease	and	causes	great	distress	in	the	child,	all	cases	will	seek	health	care	and	also	require	admission	to	TCH.			A	 standard	 form	 for	 definitive	 diagnosis	 of	 IS	 was	 used	 as	 part	 of	 the	 case	investigation	 form	 to	 provide	 a	 standardised	 method	 (7)	 for	 diagnosis	 of	 IS	 in	infants	 and	 children.	 The	 use	 of	 a	 standardised	 case	 definition	will	 improve	 the	quality	and	comparability	of	vaccine	safety	data	collected.	For	Kiribati,	only	a	level	1	 case	definition	was	 is	 available	 as	 they	do	not	 have	 the	 facilities	 to	 satisfy	 the	radiological	criteria	and	do	not	conduct	autopsies.			The	key	limitation	of	the	system	is	missing	of	cases	either	presenting	with	clinical	symptoms	that	can	be	mistaken	for	other	common	causes	such	as	dysentery.	The	symptoms	of	IS	are	also	very	distinct	with	the	distress	in	the	child	and	the	passing	of	red	currant	jelly	stools.	The	passing	of	red	currant	jelly	stools	could	be	mistaken	for	bloody	diarrhoea,	 leading	to	a	misdiagnosis	of	dysentery.	From	the	IS	review,	there	 were	 no	 cases	missed	 by	 the	medical	 record	 search	 and	 discussions	 with	clinicians.	In	addition,	during	our	review	of	records	prior	to	implementation	of	the	system	there	were	no	deaths	from	dysentery	fitting	the	case	definition.	However	to	ensure	 that	 all	 potential	 cases	 of	 IS	 have	 been	 included	 post-RV	 vaccine	introduction,	 the	 external	monitor	will	 review	 all	 hospital	 discharge	 records	 for	any	 diagnoses	 of	 IS	 or	 bowel	 obstruction	 and	 deaths	 by	 dysentery	 and	 bloody	diarrhoea	during	the	site	visit	in	2017.		




classification	 have	 been	 shown	 to	 be	 highly	 specific	 (>87%)	 (25).	 To	 ensure	reported	 cases	 are	 true	 cases,	 hospital	 records	will	 be	 reviewed	and	assessed	 to	ensure	they	fit	the	criteria.	The	case	definition	used	for	the	surveillance	system	is	based	 on	 studies	 done	 in	 both	 developed	 and	 developing	 country	 settings	 and	agreed	 upon	 by	 the	 Brighton	 Collaboration,	 a	 global	 network	 of	 vaccine	 safety	experts.	In	addition,	the	tools	used	for	classifying	cases	have	been	used	and	tested	in	many	 countries	 that	 have	 introduced	RV	 vaccine	 into	 their	 population	This	 is	especially	important	in	the	first	year	of	vaccine	introduction,	as	there	may	be	a	risk	of	over	reporting	of	cases	due	to	the	 increased	awareness	of	 the	disease.	 If	cases	are	reported	as	IS	but	this	is	not	supported	by	surgical	findings	or	clinical	criteria	then	they	will	be	omitted	from	the	reported	counts.	
Representativeness	The	system	is	representative	for	Tarawa.	TCH	is	the	only	hospital	 in	Kiribati	that	can	 provide	 the	 required	 care	 and	management	 to	 treat	 cases	 and	 is	 located	 on	Tarawa.	Thus	all	cases	of	IS	from	Tarawa	will	be	captured	here.	In	addition,	as	TCH	is	the	referral	hospital	for	Kiribati,	children	from	the	outer	islands	suffering	from	IS	will	be	referred	to	TCH	for	care.	With	the	combination	of	Tarawa	being	home	to	at	least	50%	of	the	population	and	the	referral	hospital	in	Kiribati	for	all	IS	cases,	the	results	from	the	system	can	be	extrapolated	to	the	larger	Kiribati	population.			




Stability	The	system	is	likely	to	be	stable	as	it	is	reliant	on	resources	already	in	place	for	IS	diagnosis	and	management.	The	greatest	risk	for	stability	will	be	if	key	paediatric	staff	leave	TCH.	This	is	unlikely	as	TCH	is	the	only	tertiary	hospital	in	Kiribati	and	there	are	no	other	options	in	terms	of	facilities	to	practice.	The	other	main	risk	is	as	 IS	 is	 a	 rare	 event,	 interest	 may	 wane,	 so	 regular	 contact	 between	 the	 local	coordinator	and	external	monitor	will	be	 important	to	ensure	potential	cases	are	being	 identified	 throughout	 the	 surveillance	 period.	 The	 supported	 surveillance	will	 continue	 for	3	years	post-RV	 introduction.	Three	years	post	RV	 introduction	will	give	immunisation	policy	makers	a	good	indication	of	the	risk	associated	with	RV	 use	 and	 IS	 in	 the	 Kiribati	 population.	 After	 3	 years,	 there	 will	 be	 enough	evidence	on	the	safety	of	the	vaccine	to	warrant	IS	surveillance	cessation.	

















• For	 the	next	visit,	 the	external	monitor	should	 investigate	admissions	and	the	referral	process	of	Betio	Hospital	 for	cases	of	AGE	and	SAM.	This	 is	 to	ensure	children	were	referred	onto	TCH.	This	is	to	ensure	the	AGE	and	SAM	incidences	calculated	from	the	initial	site	visit	accurately	reflect	the	burden	of	disease	 in	 the	population.	 If	 there	are	a	 substantial	number	of	 children	admitted	 and	 treated	 at	 Betio	 Hospital,	 the	 same	 review	 process	 done	 at	TCH	 previously	 should	 be	 conducted	 and	 the	 incidence	 calculations	adjusted	 to	 reflect	 these	 additional	 cases	 both	 pre	 and	 post-RV	 vaccine	introduction.		
• On	the	post-RV	vaccine	introduction	review,	to	ensure	maximal	usefulness,	it	is	imperative	that	the	external	monitor	conducts	the	following	activities:		
o Meet	 with	 the	 local	 coordinator	 to	 discuss	 the	 operation	 of	 the	surveillance	 system.	 This	 is	 to	 identify	 if	 there	 are	 issues	 or	problems	with	the	surveillance	system		
o Discuss	the	operation	of	the	surveillance	system	with	paediatric	staff	to	check	 if	 the	system	 is	 still	 acceptable	and	capturing	all	potential	cases.		
o Check	 the	medical	 records	 of	 IS	 cases	 detected	 by	 the	 surveillance	system	to	ensure	data	is	complete	and	accurate	during	their	next	site	visit.		
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1.1.	Role	Over	 the	past	 couple	of	 years,	 there	have	been	 a	number	of	 vaccine-preventable	disease	(VPD)	outbreaks	in	rural	People’s	Democratic	Republic	of	Laos	(Lao	PDR).	This	has	led	health	authorities	to	have	an	increased	interest	in	VPD	immunity,	and	consequently	 Dr	 Anonh	 Xeuatvongsa	 head	 of	 the	 National	 Immunization	Programme	(NIP)	Lao	PDR,	requested	a	serosurvey	of	Haemophilus	influenzae	type	b	 (Hib)	 antibodies	 to	 assess	 the	 immunity	 to	 Hib	 in	 the	 population.	 As	 our	PneuCAPTIVE	study	 (detailed	 in	Chapter	2)	was	already	collecting	 immunisation	data	and	sera	from	children	living	in	Vientiane	Capital	in	a	contact	serosurvey	for	pneumococcus,	 we	 were	 also	 able	 to	 use	 the	 same	 sera	 for	 detection	 of	 Hib	antibodies.			The	Hib	serosurvey	detailed	 in	 this	chapter	was	 the	work	required	 to	satisfy	 the	epidemiological	component	of	my	Masters	of	Philosophy	in	Applied	Epidemiology	(MAE).	 My	 responsibilities	 on	 the	 project	 included	 the	 design	 of	 the	 study,	preparation	of	the	documents	and	forms	needed,	overseeing	the	day-to-day	work	for	 the	contact	serosurvey,	 setting	priorities	 for	 the	project,	participation	 in	 field	work	when	 required,	maintenance	 of	 the	 study	 databases,	 training	 of	 local	 staff	and	regular	reporting	 to	 investigators.	From	this	work,	 I	will	prepare	a	report	 to	present	to	NIP	and	if	permitted,	a	manuscript	to	be	published	in	a	peer-reviewed	journal	post-MAE.			




As	 the	design	of	 the	 study	used	 convenience	 sampling,	 I	 learnt	 about	 the	 impact	this	 had	 on	 statistical	 considerations	 for	 the	 results.	 I	 learnt	 how	 to	 calculate	sample	sizes	of	varying	precision	for	different	levels	of	clustering.	In	addition,	I	had	to	 consider	 the	 potential	 effect	 measurement	 bias	 played	 in	 my	 results	 due	 to	cross-reactivity	of	other	bacteria	to	the	Hib	assay.				
1.3.	Public	Health	implications	and	impact	Since	 the	 development	 and	 widespread	 use	 of	 Hib	 vaccines,	 incidence	 of	 Hib	disease	has	significantly	decreased.	However,	in	more	recent	times,	some	countries	have	 seen	an	 increase	 in	Hib	 incidence	and	also	breakthrough	disease.	This	data	contributes	to	the	knowledge	of	Hib	in	the	region.	This	is	the	first	Hib	serosurvey	done	in	the	region	and	provides	an	example	of	the	situation	in	Southeast	Asia	and	supports	the	recommendation	for	continued	surveillance	of	Hib	disease	to	ensure	there	is	no	increase	post-Hib	vaccine	introduction.			Based	 on	 recent	 serosurveys	 for	 hepatitis	 B	 (HepB)	 and	 measles	 conducted	 in	various	Lao	PDR,	coupled	with	VPD	outbreaks,	there	are	concerns	between	what	is	recorded	either	on	the	mother-child	health	(MCH)	card	or	immunisation	registers	and	the	serological	 immunity	in	the	population.	This	has	flowed	into	Hib	disease,	where	there	are	concerns	children	in	the	wider	population	are	not	protected.	The	results	from	this	study	attempt	to	address	these	questions	by	describing	both	the	vaccination	status	by	written	record	and	serological	immunity	in	the	same	sample	population.	Currently	 there	 is	no	booster	dose	 in	 the	 schedule	 and	based	on	 the	results	 for	 this	work	 there	 is	no	recommendation	 to	add	a	booster	dose	 into	 the	schedule.	 However,	 the	 written	 record	 vaccine	 coverage	 from	 this	 study	 was	similar	 to	 the	 NIP	 estimates	 for	 Vientiane	 Capital.	 However	 these	 estimates	 are	lower	than	both	the	regional	and	global	estimates	of	DTP-Hib-HepB	vaccine,	giving	NIP	further	impetus	to	continue	improving	vaccine	coverage	through	both	old	and	alternative	vaccination	efforts.			









Background/aims:	People’s	Democratic	Republic	of	Laos	(Lao	PDR)	has	suffered	in	recent	 times	 from	outbreaks	of	 vaccine-preventable	disease	 (VPD),	 leading	 to	an	increase	in	concerns	the	population	was	not	protected	from	other	VPDs	such	as	H.	
influenzae	type	b	(Hib).	The	aim	of	the	study	in	Vientiane	Capital	was	to	report	the	vaccination	 coverage	by	written	 record	 in	 children	<5	 years	 of	 age	 and	describe	evidence	of	serological	protection	to	Hib	from	these	same	children.			
Methods:	 A	 convenience	 sample	 of	 children	 <5	 years	 of	 age	 living	 in	 Vientiane	Capital	was	used	to	determine	coverage	by	written	record	for	Hib	vaccine	(given	as	part	 of	DTPw-Hib-HepB	 vaccine).	 A	 subset	 of	 these	 children	 aged	 12-59	months	had	 a	 blood	 sample	 taken	 to	 test	 for	 IgG	 antibody	 levels	 to	 Hib	 capsular	polysaccharide,	polyribosylribitol	phosphate	(PRP).	Vaccination	status	was	defined	as	children	having	received	3	doses	of	Hib	vaccine.	Written	record	was	defined	as	either	 the	 parent-held	 mother	 child	 handbook	 (MCH)	 containing	 the	 record	 of	vaccination	 or	 via	 immunisation	 registers	 held	 at	 the	 child’s	 health	 centre.	Evidence	of	serological	protection	was	defined	as	short	and	long-term	with	cut-offs	being	 ≥0.15μg/ml	 and	 ≥1.0μg/ml,	 respectively.	 Chi-squared	 tests	 and	 95%	confidence	intervals	were	used	to	compare	groups.			




children	by	written	 record	had	 serological	 evidence	of	 short-term	 immunity	 and	23%	had	evidence	of	long-term	immunity.		






H.	 influenzae	 is	 a	 Gram-negative	 coccobacillus,	 of	 both	 capsulated	 and	 non-encapsulated	types.	H.	influenzae	 type	b	(Hib)	 is	 the	most	pathogenic,	accounting	for	>90%	of	systemic	infections.	H.	influenzae	type	b	primarily	causes	pneumonia	and	meningitis	 almost	 exclusively	 in	 children	 <5	 years	 of	 age.	 In	 2000,	 Hib	was	estimated	 to	 have	 caused	 approximately	 2-3million	 cases	 of	 serious	 disease	 and	386,000	 deaths	 in	 young	 children	 worldwide,	 with	 peak	 incidence	 in	 those	younger	than	6	months	of	age.	Transmission	occurs	through	infectious	respiratory	droplets	(1).			The	 best	method	 of	 Hib	 disease	 prevention	 is	 through	 the	 use	 of	 Hib	 conjugate	vaccines.	 H.	 influenzae	 type	 b	 vaccines	 have	 been	 available	 since	 the	 1980s,	however	widespread	vaccination	did	not	occur	until	 the	2000s.	With	widespread	routine	vaccination,	Hib	meningitis	has	largely	been	eliminated	from	high-income	countries	 (HICs)	 and	 low-	 and	 middle-income	 countries	 (LMICs)	 that	 have	introduced	 Hib	 vaccines	 into	 their	 population	 (1).	 Hib	 vaccine	 is	 available	 in	 a	monovalent	 form	 or	 in	 combination	 vaccines	 containing	 diphtheria	 (DTP),	reducing	the	number	of	injections	needed	to	cover	infants	from	common	childhood	diseases	(2).			

















identification	of	factors	that	may	predict	low	coverage	and	also	waning	immunity	in	a	population	(3).	Serosurveys	rely	on	the	collection	of	samples,	most	commonly	blood	or	related	fluids,	to	test	for	the	prevalence	of	antibodies	in	individuals	from	a	population	 (6).	 Serosurveys	 can	 include	 serum	 collected	 for	 other	 purposes	 or	specifically	 to	 address	 a	 research	 question.	 The	 key	 limitations	 are	 the	 potential	high	 costs	 associated	 with	 conducting	 a	 serosurvey,	 selection	 process	 and	 if	 a	reliable	 correlate	 of	 protection	 exists.	 Serosureys	 can	be	prone	 to	 selection	bias,	especially	if	they	rely	on	serum	collected	for	a	different	purpose.	If	there	is	no	clear	correlate	of	protection,	they	cannot	distinguish	between	vaccination	and	naturally	acquired	 immunity	 (3).	 In	LMIC	 settings,	 specimen	collection,	 reliable	 laboratory	assays	and	appropriate	statistical	analysis	have	been	a	hindrance	to	their	use	(6).	However,	serosurveys	can	be	very	useful	 to	help	design	and	monitor	vaccination	programs	(6).			








was	 recommended	 (27).	 In	 contrast,	using	 the	 same	 infant	 schedule	as	Kenya	 (3	doses	 with	 no	 booster),	 the	 Gambia	 has	 seen	 a	 gradual	 increase	 in	 Hib	 disease	incidence	in	children	2-59	months	of	age	in	the	post-Hib	vaccine	era	(28).	Seventy	per	 cent	 of	 children	 5-6	 years	 of	 age	 had	 evidence	 of	 long-term	 protective	antibodies	in	the	Gambia	(28).	However,	there	is	no	recommendation	to	introduce	a	 booster	 dose	 as	 questions	 remain	 of	 necessity,	 age	 and	 also	what	 factors	may	influence	 resurgence	 of	 Hib	 disease	 in	 LMIC	 settings.	 Regardless,	 ongoing	surveillance	 is	 important	 in	 order	 to	 detect	 changes	 in	Hib	disease	 after	 vaccine	introduction	and	is	recommended	by	all	studies.			





3.5.	Aims	and	objectives	The	 aims	 of	 this	 study	 were	 to	 determine	 in	 children	 <5years	 of	 age	 living	 in	Vientiane	Capital:	1. The	percentage	of	children	vaccinated	with	Hib	vaccine,	based	on	written	immunisation	records;	2. The	percentage	of	children	aged	12-59	months	with	serological	evidence	of	Hib	protection;	and	3. What	percentage	of	 the	unvaccinated	children	have	serological	evidence	of	Hib	protection.		 To	achieve	the	study	aims,	the	following	objectives	from	a	convenient	sample	of	children	<5	years	of	age	living	in	Vientiane	Capital,	Lao	PDR	were	to	calculate	the:	
• Coverage	of	Hib	 vaccine	 from	written	 immunisation	 record	 (parent-held	card	or	health	centre	immunisation	register),	by	age	group	and	sex;	










4.2.	Recruitment	and	data	collection	A	convenience	sample	of	children	<5	years	of	age	living	in	Vientiane	Capital	were	recruited	 from	 contacts	 of	 children	 hospitalised	with	 acute	 respiratory	 infection	(refer	to	Chapter	2	for	details	regarding	the	recruitment	of	these	cases)	as	part	of	another	ongoing	study.				After	consent	had	been	sought	from	cases	to	conduct	the	contact	serosurvey,	a	list	of	 all	 contacts	were	 identified	 from	 the	 case’s	 parent/guardian	 and	 listed	 in	 the	screening	 book,	 with	 each	 contact	 given	 a	 unique	 study	 identification	 number.	Parents	of	contacts	were	contacted	either	by	phone	or	in	person	and	had	the	study	explained	to	them	with	the	use	of	an	information	sheet	(Appendix	A).		Consent	was	 obtained	 from	parents	 in	 two	 stages.	 First	 they	were	 asked	 to	 give	consent	 to	 be	 part	 of	 the	 written	 record	 survey,	 which	 included	 viewing	 and	recording	 their	 child’s	 vaccination	 status	 from	 their	 MCH	 card	 or	 to	 find	 their	record	at	the	health	centre.	The	second	stage	of	consent	was	for	the	serosurvey.	If	the	 child	 was	 >12	 months	 old,	 parents	 were	 asked	 to	 give	 consent	 for	 a	 blood	sample	 to	 be	 taken.	 If	 consent	 was	 given	 for	 the	 blood	 sample,	 up	 to	 1ml	 was	collected,	 using	 aseptic	 technique	 by	 finger	 prick.	 Blood	 samples	 were	 then	transported	to	the	LOMWRU	laboratory	in	a	cool	box	on	the	day	of	collection.		For	 both	 the	 written	 record	 and	 serosurvey,	 basic	 demographic	 data	 were	collected	on	a	dedicated	data	collection	form	(Appendix	B).	Data	collected	included	date	of	birth/age,	sex,	ethnicity	and	where	they	seek	medical	care	for	their	child.			






4.4.1.	Written	record	Using	 either	 the	 MCH	 card	 or	 health	 centre	 immunisation	 registry,	 participants	that	had	received	3	doses	of	vaccine	were	considered	fully	vaccinated.	Participants	receiving	2	doses	or	less	were	considered	undervaccinated.		
4.4.2.	Serological	evidence	of	Hib	antibody	protection	For	determining	Hib	antibody	levels	in	serum	samples,	ELISAs	measuring	IgG	anti-PRP	 levels	were	 performed	with	 samples	 containing	 ≥0.15μg/ml	 and	 ≥1.0μg/ml	considered	evidence	of	short	and	long-term	immunity,	respectively.			
4.5.	Statistical	consideration	Continuous	variables	such	as	age	were	summarised	using	median	and	interquartile	range.	 Discrete	 variables	 including	 sex,	 ethnicity	 and	 health	 seeking	 behaviours,	were	 summarised	 using	 frequency	 counts	 and	 percentages.	 P-values	 were	calculated	 using	 chi-squared	 tests.	Ninety-five	 percent	 confidence	 intervals	were	reported	 for	 proportion	 calculations	 of	 written	 record	 coverage	 and	 antibody	levels.		All	statistical	tests	were	considered	significant	at	the	0.05%	level.	




Thus	 for	 the	primary	aim	of	vaccine	coverage	by	written	record,	prevalence	was	estimated	 in	 the	 sample	 to	be	within	5	of	 the	estimated	coverage	of	77%.	 In	 the	sample	 there	were	168	clusters,	with	cluster	size	ranging	 from	1-20.	Taking	 into	consideration	the	effect	of	 the	 ICC	the	sample	size	required	 for	 the	 following	 ICC	values	are	shown	in	Table	1:		
Table	 1:	Written	 record	 of	 vaccination	 sample	 size	 calculations	with	 differing	 levels	 of	intra-cluster	 correlation	 (ICC)	 at	 5%	 precision,	 95%	 confidence	 in	 comparison	 to	nationally	reported	vaccination	coverage	of	77%	in	the	12-23month	age	group	ICC	value	 0.01	 0.02	 0.03	 0.05	 0.1	Sample	size	(5%	precision)	 274.7	 276.5	 278.4	 282.3	 293.4		
4.5.2.	Evidence	of	serological	protection	Based	 on	 the	 literature,	 the	 proportion	 of	 vaccinated	 children	 2-5	 years	 of	 age	showing	evidence	for	short	and	long-term	immunity	ranged	77-100%	and	19-83%,	respectively	 (19-23,	 25).	 However,	 because	 the	 children	 in	 this	 study	 received	their	 last	 vaccinations	 at	 14	weeks	 of	 age,	 only	 evidence	 of	 long-term	 immunity	was	relevant	for	the	purposes	of	sample	size	calculations.			In	 the	 sample	 there	 were	 49	 clusters	 ranging	 in	 size	 from	 1-10.	 Taking	 into	consideration	the	effect	of	the	ICC,	the	sample	size	required	for	the	following	ICC	values	are	shown	in	Table	2	for	long-term	immunity:		
Table	 2:	 Evidence	 of	 long-term	 antibodies	 to	 H.	 influenzae	 type	 b	 (Hib)	 sample	 size	calculations	with	differing	levels	of	intra-cluster	(ICC)	at	5%	precision,	95%	confidence	in	comparison	to	the	range	19-83%	reported	in	the	literature	ICC	value	 0.01	 0.02	 0.03	 0.05	 0.1	Sample	size	(5%	confidence)	 224.8-246.6	 233.3-257.1	 242.7-268.9	 264.8-297.0	 350.5-413.1		




5.	Results	From	the	1st	of	May	2015	until	the	28th	of	February	2017,	there	were	935	contacts	screened	for	both	written	record	and	serological	evidence	for	Hib	vaccination.	For	the	written	record	and	serological	evidence	a	total	of	559	and	262	were	included	in	 the	 study,	 respectively.	 The	 flowchart	 for	 the	 inclusion	 of	 contacts	 for	 both	surveys	can	be	seen	in	Figure	2.			
Figure	 2:	 Flowchart	 of	 participant	 recruitment	 into	 the	 written	 record	 and	 serological	evidence	survey,	from	May	2015	to	February	2017	
Written	record	survey	 Serological	survey	
	























5.1.	Hib	vaccination	coverage	The	 total	 coverage	 of	 Hib	 vaccine	 (given	 as	 part	 of	 DTPw-Hib-HepB	 vaccine)	 by	written	record	was	62%	(348/559).	Vaccination	status	was	unknown	for	65	cases.	Contacts	 12-23	 months	 of	 age	 had	 significantly	 higher	 coverage	 than	 other	 age	groups	at	74%	(p<0.001).	Coverage	of	different	age	groups	can	be	seen	in	Figure	3.			






5.2.	Serological	evidence	Of	the	553	contacts	eligible	for	the	serosurvey,	322	provided	consent.	Of	those,	262	blood	 samples	were	 included	 in	 the	 final	 analysis	 (Figure	 2).	 All	 contacts	 tested	had	serological	evidence	of	short-term	protection.	Sixty	percent	(95%	CI	54-66%)	of	contacts	tested	had	serological	evidence	of	long-term	protection.	There	was	no	significant	difference	between	 age	 groups	 (p=0.492)	 (Figure	4)	 or	 sex	 (p=0.482)	for	long-term	seroprotective	levels.			
Figure	 4:	 Proportion	 of	 samples	with	 short-	 and	 long-term	 antibodies	 for	H.	 influenzae	type	b	(Hib)	by	age	(bars	indicate	95%	CI)	
	Samples	with	antibodies	>0.15ug/ml	are	positive	for	short-term	immunity.	Samples	with	antibodies	>1.0ug/ml	are	positive	for	long-term	immunity.		













































• Given	 the	 levels	 of	 Hib	 vaccine	 found	 in	 the	 study	were	 lower	 than	 both	regional	 and	 global	 estimates,	 ongoing	 efforts	 by	 NIP	 and	WHO	 to	 boost	vaccination	 rates	 should	 be	 supported.	 These	 may	 include	 outreach	programs,	 both	 education	 and	 mobile	 vaccination	 units.	 Considering	 the	resources	available,	the	education	component	could	be	supported	by	village	health	 volunteers	 and	 for	 the	 mobile	 vaccination	 units,	 these	 could	 be	deployed	on	dedicated	days.		
• Hib	 surveillance	 is	 already	 conducted	 at	 sentinel	 sites	 such	 as	 Mahosot	Hospital.	However	the	number	of	cerebrospinal	and	blood	samples	 is	 low.	Ways	 to	 improve	 this	 could	 be	 through	 increasing	 clinician	 awareness	 of	the	 importance	 of	 Hib	 surveillance	 and	 financial	 support	 for	 testing.	Considering	 the	available	resources,	 this	 is	achievable	with	 the	support	of	senior	paediatric	staff.	
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to	 be	 trained	 on	 the	 identification	 and	 consent	 process	 of	 contacts,	 subsequent	data	collection	on	dedicated	 forms	and	entry	of	data	 into	 the	relevant	databases.	For	the	health	centre	immunisation	register	data	collection	staff	had	to	be	trained	on	the	process	of	understanding	the	data	contained	in	the	registries,	as	each	health	centre	 recorded	 the	 data	 differently,	 how	 to	 collect	 the	 data	 contained	 in	 the	registries	and	finally	the	data	entry	process.	The	data	for	both	the	serosurvey	and	health	 centre	 registries	 were	 double	 data	 entered	 into	 Epidata	 databases.	
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